{"protocolSection":{"identificationModule":{"nctId":"NCT00526474","orgStudyIdInfo":{"id":"P04737"},"secondaryIdInfos":[{"id":"TRA 2°P - TIMI 50"},{"id":"2006-002942-12"},{"id":"MK-5348-015","type":"OTHER","domain":"Merck Study Number"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P - TIMI 50)"},"statusModule":{"statusVerifiedDate":"2018-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-09-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2011-12-01","type":"ACTUAL"},"completionDateStruct":{"date":"2011-12-01","type":"ACTUAL"},"studyFirstSubmitDate":"2007-09-06","studyFirstSubmitQcDate":"2007-09-06","studyFirstPostDateStruct":{"date":"2007-09-10","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-05-16","resultsFirstSubmitQcDate":"2014-05-16","resultsFirstPostDateStruct":{"date":"2014-06-18","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-08-22","lastUpdatePostDateStruct":{"date":"2018-09-21","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"collaborators":[{"name":"The Thrombolysis in Myocardial Infarction Study (TIMI) Group","class":"UNKNOWN"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The study is designed to determine whether vorapaxar, when added to the existing standard of care (SOC) for preventing heart attack and stroke (eg, aspirin, clopidogrel) in participants with a known history of atherosclerosis, will yield additional benefit over the existing standard of care without vorapaxar in preventing heart attack and stroke.\n\nThe study is also designed to assess risk of bleeding with vorapaxar added to the standard of care versus the standard of care alone."},"conditionsModule":{"conditions":["Atherosclerosis","Ischemia","Myocardial Infarction","Cerebrovascular Accident","Peripheral Arterial Disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":26449,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.","interventionNames":["Drug: Placebo"]},{"label":"Vorapaxar","type":"EXPERIMENTAL","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.","interventionNames":["Drug: Vorapaxar"]}],"interventions":[{"type":"DRUG","name":"Vorapaxar","description":"2.5-mg tablet daily for at least 1 year","armGroupLabels":["Vorapaxar"]},{"type":"DRUG","name":"Placebo","description":"matching tablet daily for at least 1 year","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, or Urgent Coronary Revascularization (UCR) Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, or UCR. A Clinical Endpoints Committee (CEC) reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, or UCR within 3 years from randomization.","timeFrame":"up to 3 years"}],"secondaryOutcomes":[{"measure":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, or Stroke Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, or stroke. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, or stroke within 3 years from randomization.","timeFrame":"up to 3 years"},{"measure":"Kaplan-Meier Estimate of the Percentage of Participants Who Met Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) Moderate or Severe Bleeding Criteria Within 3 Years From Randomization","description":"Adverse events were categorized as \"bleeding events\" if the intensity, frequency, or type of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the GUSTO cooperative group criteria as follows: Mild , Moderate or Severe and the grading was adjudicated by the CEC. The Kaplan-Meier estimate reports the percentage of participants who experienced GUSTO moderate or severe bleeding within 3 years from randomization.","timeFrame":"up to 3 years"},{"measure":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Clinically Significant Bleeding Within 3 Years From Randomization","description":"Adverse events were categorized as \"bleeding events\" if the intensity, frequency, or type of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the Thrombolysis in Myocardial Infarction (TIMI) Study Group criteria as major, minor or other. \"Clinically Significant Bleeding\" was defined as the composite of TIMI Major bleeding, TIMI Minor bleeding, or bleeding that required unplanned medical or surgical treatment or unplanned laboratory evaluation even if it did not meet the criteria for TIMI major or minor bleeding. The Kaplan-Meier estimate reports the percentage of participants who experienced clinically significant bleeding within 3 years from randomization.","timeFrame":"up to 3 years"},{"measure":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Death From Any Cause, MI, Stroke, or UCR Within 3 Years From Randomization","description":"The time (in days) from study start to the occurrence of any of the following clinical outcomes was recorded: death from any cause, MI, stroke, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who experienced death from any cause, MI, stroke, or UCR within 3 years from randomization.","timeFrame":"up to 3 years"},{"measure":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death or an MI Within 3 Years From Randomization","description":"The time (in days) from study start to the occurrence of CV death or MI. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death or MI within 3 years from randomization.","timeFrame":"up to 3 years"},{"measure":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, UCR, or Urgent Hospitalization for Vascular Cause of Ischemic Nature (UH-VCIN) Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, UCR or UH-VCIN. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, UCR, or UH-VCIN within 3 years from randomization.","timeFrame":"up to 3 years"},{"measure":"Kaplan-Meier Estimate of the Percentage of Participants Who Died From Any Cause, or Experienced an MI, Stroke, or Any Revascularization Within 3 Years From Randomization","description":"The time (in days) from study start to death from any cause or the first occurrence of any of the following clinical outcomes was recorded: MI, stroke, or any revascularization procedure . A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who died from any cause, or experienced an MI, stroke, or any revascularization within 3 years from randomization.","timeFrame":"up to 3 years"},{"measure":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, Any Revascularization, or UH-VCIN Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, any revascularization, or UH-VCIN. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, any revascularization procedure, or UH-VCIN within 3 years from randomization.","timeFrame":"up to 3 years"},{"measure":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death Within 3 Years From Randomization","description":"The time (in days) from study start to CV death (if reported) was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death within 3 years from randomization.","timeFrame":"up to 3 years"},{"measure":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced an MI Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of an MI was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced an MI within 3 years from randomization.","timeFrame":"up to 3 years"},{"measure":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced UCR Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of UCR was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced UCR within 3 years from randomization.","timeFrame":"up to 3 years"},{"measure":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced a Stroke Within 3 Years From Randomization","description":"The time (in days) from study start to first experience of a stroke was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced a stroke within 3 years from randomization.","timeFrame":"up to 3 years"},{"measure":"Kaplan-Meier Estimate of the Percentage of Participants Who Died From Any Cause Within 3 Years From Randomization","description":"The time (in days) from study start to death from any cause was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who died from any cause within 3 years from randomization.","timeFrame":"up to 3 years"},{"measure":"Kaplan-Meier Estimate of the Percentage of Participants Who Had a UH-VCIN Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of an UH-VCIN was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who had a UH-VCIN within 3 years from randomization.","timeFrame":"up to 3 years"},{"measure":"Kaplan-Meier Estimate of the Percentage of Participants Who Had Any Revascularization Performed Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of a revascularization was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who had any revascularization performed within 3 years from randomization.","timeFrame":"up to 3 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nMen and women at least 18 years old with evidence or a history of atherosclerosis involving the coronary, cerebral, or peripheral vascular systems by one or more of the following:\n\n* history of myocardial infarction (heart attack)\n* history of ischemic stroke (stroke due to a blocked artery)\n* history of peripheral arterial disease\n\nExclusion Criteria:\n\n* history of intracranial hemorrhage or of central nervous system (CNS) surgery, tumor, or aneurysm\n* any bleeding disorder or abnormality\n* sustained severe hypertension or valvular heart disease\n* current or recent platelet count \\<100,000 mm\\^3\n* planned or ongoing treatment with a blood thinning medication\n* pregnancy\n* any significant medical or physiological condition or abnormality that could put the subject at increased risk or limit the subject's ability to participate for the duration of the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}]},"referencesModule":{"references":[{"pmid":"35224730","type":"DERIVED","citation":"Natale P, Palmer SC, Saglimbene VM, Ruospo M, Razavian M, Craig JC, Jardine MJ, Webster AC, Strippoli GF. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD008834. doi: 10.1002/14651858.CD008834.pub4."},{"pmid":"33884889","type":"DERIVED","citation":"Berg DD, Freedman BL, Bonaca MP, Jarolim P, Scirica BM, Goodrich EL, Sabatine MS, Morrow DA. Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2 degrees P-TIMI 50. J Am Heart Assoc. 2021 May 4;10(9):e018673. doi: 10.1161/JAHA.120.018673. Epub 2021 Apr 22."},{"pmid":"32000630","type":"DERIVED","citation":"Qamar A, Morrow DA, Creager MA, Scirica BM, Olin JW, Beckman JA, Murphy SA, Bonaca MP. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2 degrees P-TIMI 50 trial. Vasc Med. 2020 Apr;25(2):124-132. doi: 10.1177/1358863X19892690. Epub 2020 Jan 30."},{"pmid":"31642690","type":"DERIVED","citation":"Xu H, Bonaca MP, Goodrich E, Scirica BM, Morrow DA. Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2 degrees P-TIMI 50 Trial. Eur Heart J Acute Cardiovasc Care. 2019 Oct 23:2048872619883354. doi: 10.1177/2048872619883354. Online ahead of print."},{"pmid":"33609100","type":"DERIVED","citation":"Xu H, Bonaca MP, Goodrich E, Scirica BM, Morrow DA. Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2 degrees P-TIMI 50 Trial. Eur Heart J Acute Cardiovasc Care. 2019 Oct 23:2048872619883354. doi: 10.1177/2048872619883354. Online ahead of print."},{"pmid":"27765312","type":"DERIVED","citation":"Bonaca MP, Creager MA, Olin J, Scirica BM, Gilchrist IC Jr, Murphy SA, Goodrich EL, Braunwald E, Morrow DA. Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2 degrees P-TIMI 50 Trial. JACC Cardiovasc Interv. 2016 Oct 24;9(20):2157-2164. doi: 10.1016/j.jcin.2016.07.034."},{"pmid":"27440003","type":"DERIVED","citation":"Bohula EA, Bonaca MP, Braunwald E, Aylward PE, Corbalan R, De Ferrari GM, He P, Lewis BS, Merlini PA, Murphy SA, Sabatine MS, Scirica BM, Morrow DA. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. Circulation. 2016 Jul 26;134(4):304-13. doi: 10.1161/CIRCULATIONAHA.115.019861."},{"pmid":"27431644","type":"DERIVED","citation":"Kidd SK, Bonaca MP, Braunwald E, De Ferrari GM, Lewis BS, Merlini PA, Murphy SA, Scirica BM, White HD, Morrow DA. Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50. J Am Heart Assoc. 2016 Jul 18;5(7):e003237. doi: 10.1161/JAHA.116.003237."},{"pmid":"26876014","type":"DERIVED","citation":"Berg DD, Bonaca MP, Braunwald E, Corbalan R, Goto S, Kiss RG, Murphy SA, Scirica BM, Spinar J, Morrow DA. Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2 degrees P-TIMI 50). Am J Cardiol. 2016 Apr 1;117(7):1055-8. doi: 10.1016/j.amjcard.2015.12.052. Epub 2016 Jan 14."},{"pmid":"26826179","type":"DERIVED","citation":"Bonaca MP, Gutierrez JA, Creager MA, Scirica BM, Olin J, Murphy SA, Braunwald E, Morrow DA. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2 degrees P-TIMI 50). Circulation. 2016 Mar 8;133(10):997-1005. doi: 10.1161/CIRCULATIONAHA.115.019355. Epub 2016 Jan 29."},{"pmid":"26338971","type":"DERIVED","citation":"Bohula EA, Aylward PE, Bonaca MP, Corbalan RL, Kiss RG, Murphy SA, Scirica BM, White H, Braunwald E, Morrow DA. Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2 degrees P-TIMI 50. Circulation. 2015 Nov 17;132(20):1871-9. doi: 10.1161/CIRCULATIONAHA.114.015042. Epub 2015 Sep 3."},{"pmid":"25792124","type":"DERIVED","citation":"Magnani G, Bonaca MP, Braunwald E, Dalby AJ, Fox KA, Murphy SA, Nicolau JC, Oude Ophuis T, Scirica BM, Spinar J, Theroux P, Morrow DA. Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc. 2015 Mar 19;4(3):e001505. doi: 10.1161/JAHA.114.001505. Erratum In: J Am Heart Assoc. 2015 Apr;4(4). pii: e000633. doi: 10.1161/JAHA.115.000633."},{"pmid":"25681464","type":"DERIVED","citation":"Cavender MA, Scirica BM, Bonaca MP, Angiolillo DJ, Dalby AJ, Dellborg M, Morais J, Murphy SA, Ophuis TO, Tendera M, Braunwald E, Morrow DA. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. Circulation. 2015 Mar 24;131(12):1047-53. doi: 10.1161/CIRCULATIONAHA.114.013774. Epub 2015 Feb 13."},{"pmid":"25465417","type":"DERIVED","citation":"Bonaca MP, Scirica BM, Braunwald E, Wiviott SD, Goto S, Nilsen DW, Bonarjee V, Murphy SA, Morrow DA. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 degrees P-TIMI 50 trial. J Am Coll Cardiol. 2014 Dec 9;64(22):2318-26. doi: 10.1016/j.jacc.2014.07.997. Epub 2014 Dec 1."},{"pmid":"25465416","type":"DERIVED","citation":"Bonaca MP, Scirica BM, Braunwald E, Wiviott SD, O'Donoghue ML, Murphy SA, Morrow DA. Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2 degrees P-TIMI 50 trial. J Am Coll Cardiol. 2014 Dec 9;64(22):2309-17. doi: 10.1016/j.jacc.2014.09.037. Epub 2014 Dec 1."},{"pmid":"23501976","type":"DERIVED","citation":"Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, Lamp JM, Murphy SA, Braunwald E, Morrow DA. Vorapaxar in patients with peripheral artery disease: results from TRA2degreesP-TIMI 50. Circulation. 2013 Apr 9;127(14):1522-9, 1529e1-6. doi: 10.1161/CIRCULATIONAHA.112.000679. Epub 2013 Mar 15."},{"pmid":"23396280","type":"DERIVED","citation":"Morrow DA, Alberts MJ, Mohr JP, Ameriso SF, Bonaca MP, Goto S, Hankey GJ, Murphy SA, Scirica BM, Braunwald E; Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Steering Committee and Investigators. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013 Mar;44(3):691-8. doi: 10.1161/STROKEAHA.111.000433. Epub 2013 Feb 8."},{"pmid":"22932716","type":"DERIVED","citation":"Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS, Mehrhof F, Merlini PA, Murphy SA, Sabatine MS, Tendera M, Van de Werf F, Wilcox R, Morrow DA; TRA 2 degrees P-TIMI 50 Steering Committee Investigators. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial. Lancet. 2012 Oct 13;380(9850):1317-24. doi: 10.1016/S0140-6736(12)61269-0. Epub 2012 Aug 26."},{"pmid":"22443427","type":"DERIVED","citation":"Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012 Apr 12;366(15):1404-13. doi: 10.1056/NEJMoa1200933. Epub 2012 Mar 24."},{"pmid":"19699854","type":"DERIVED","citation":"Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, Bonaca MP, Fish P, McCabe CH, Braunwald E; TRA 2(o)P-TIMI 50 Investigators. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J. 2009 Sep;158(3):335-341.e3. doi: 10.1016/j.ahj.2009.06.027."}],"availIpds":[{"type":"CSR Synopsis","url":"http://www.merck.com/clinical-trials/study.html?id=P04737&kw=P04737&tab=access"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf","url":"http://engagezone.msd.com/ds_documentation.php"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"The Intent to Treat (ITT) Population, defined as all enrolled participants who were randomly assigned to a treatment group.","recruitmentDetails":"Prior to planned study completion, the Data Safety Monitoring Board (DSMB) recommended discontinuation of study drug in all participants with a pre- or post-randomization history of stroke. A total of 4510 participants had study medication stopped, however these participants were included in the overall population for efficacy and safety analyses.","groups":[{"id":"FG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"FG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"13224"},{"groupId":"FG001","numSubjects":"13225"}]},{"type":"Received Study Drug","achievements":[{"groupId":"FG000","numSubjects":"13166"},{"groupId":"FG001","numSubjects":"13186"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"12932"},{"groupId":"FG001","numSubjects":"12953"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"292"},{"groupId":"FG001","numSubjects":"272"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The Intent to Treat (ITT) Population, defined as all enrolled participants who were randomly assigned to a treatment group.","groups":[{"id":"BG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"BG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"13224"},{"groupId":"BG001","value":"13225"},{"groupId":"BG002","value":"26449"}]}],"measures":[{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"<65 years","categories":[{"measurements":[{"groupId":"BG000","value":"8273"},{"groupId":"BG001","value":"8188"},{"groupId":"BG002","value":"16461"}]}]},{"title":"65-<75 years","categories":[{"measurements":[{"groupId":"BG000","value":"3445"},{"groupId":"BG001","value":"3523"},{"groupId":"BG002","value":"6968"}]}]},{"title":">=75 years","categories":[{"measurements":[{"groupId":"BG000","value":"1506"},{"groupId":"BG001","value":"1514"},{"groupId":"BG002","value":"3020"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"3172"},{"groupId":"BG001","value":"3154"},{"groupId":"BG002","value":"6326"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"10052"},{"groupId":"BG001","value":"10071"},{"groupId":"BG002","value":"20123"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, or Urgent Coronary Revascularization (UCR) Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, or UCR. A Clinical Endpoints Committee (CEC) reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, or UCR within 3 years from randomization.","populationDescription":"Intent to Treat (ITT) Population, defined as all participants who were randomly assigned to a treatment arm.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13224"},{"groupId":"OG001","value":"13225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.4"},{"groupId":"OG001","value":"11.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.001","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.88","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.82","ciUpperLimit":"0.95","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, or Stroke Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, or stroke. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, or stroke within 3 years from randomization.","populationDescription":"ITT Population, defined as all participants who were randomly assigned to a treatment arm.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13224"},{"groupId":"OG001","value":"13225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5"},{"groupId":"OG001","value":"9.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.87","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.80","ciUpperLimit":"0.94","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Met Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) Moderate or Severe Bleeding Criteria Within 3 Years From Randomization","description":"Adverse events were categorized as \"bleeding events\" if the intensity, frequency, or type of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the GUSTO cooperative group criteria as follows: Mild , Moderate or Severe and the grading was adjudicated by the CEC. The Kaplan-Meier estimate reports the percentage of participants who experienced GUSTO moderate or severe bleeding within 3 years from randomization.","populationDescription":"As Treated Population, which included all participants who received at least 1 dose of study medication.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13166"},{"groupId":"OG001","value":"13186"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9"},{"groupId":"OG001","value":"4.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"1.51","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.31","ciUpperLimit":"1.74","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Clinically Significant Bleeding Within 3 Years From Randomization","description":"Adverse events were categorized as \"bleeding events\" if the intensity, frequency, or type of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the Thrombolysis in Myocardial Infarction (TIMI) Study Group criteria as major, minor or other. \"Clinically Significant Bleeding\" was defined as the composite of TIMI Major bleeding, TIMI Minor bleeding, or bleeding that required unplanned medical or surgical treatment or unplanned laboratory evaluation even if it did not meet the criteria for TIMI major or minor bleeding. The Kaplan-Meier estimate reports the percentage of participants who experienced clinically significant bleeding within 3 years from randomization.","populationDescription":"As Treated Population, which included all participants who received at least 1 dose of study medication.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13166"},{"groupId":"OG001","value":"13186"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3"},{"groupId":"OG001","value":"15.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"1.41","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.31","ciUpperLimit":"1.51","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Death From Any Cause, MI, Stroke, or UCR Within 3 Years From Randomization","description":"The time (in days) from study start to the occurrence of any of the following clinical outcomes was recorded: death from any cause, MI, stroke, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who experienced death from any cause, MI, stroke, or UCR within 3 years from randomization.","populationDescription":"ITT Population, defined as all participants who were randomly assigned to a treatment arm.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Perentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13224"},{"groupId":"OG001","value":"13225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2"},{"groupId":"OG001","value":"13.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.009","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.91","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.85","ciUpperLimit":"0.98","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death or an MI Within 3 Years From Randomization","description":"The time (in days) from study start to the occurrence of CV death or MI. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death or MI within 3 years from randomization.","populationDescription":"ITT Population, defined as all participants who were randomly assigned to a treatment arm.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13224"},{"groupId":"OG001","value":"13225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2"},{"groupId":"OG001","value":"7.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.002","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.78","ciUpperLimit":"0.94","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, UCR, or Urgent Hospitalization for Vascular Cause of Ischemic Nature (UH-VCIN) Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, UCR or UH-VCIN. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, UCR, or UH-VCIN within 3 years from randomization.","populationDescription":"ITT Population, defined as all participants who were randomly assigned to a treatment arm.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13224"},{"groupId":"OG001","value":"13225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7"},{"groupId":"OG001","value":"13.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.87","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.81","ciUpperLimit":"0.93","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Died From Any Cause, or Experienced an MI, Stroke, or Any Revascularization Within 3 Years From Randomization","description":"The time (in days) from study start to death from any cause or the first occurrence of any of the following clinical outcomes was recorded: MI, stroke, or any revascularization procedure . A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who died from any cause, or experienced an MI, stroke, or any revascularization within 3 years from randomization.","populationDescription":"ITT Population, defined as all participants who were randomly assigned to a treatment arm.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13224"},{"groupId":"OG001","value":"13225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.6"},{"groupId":"OG001","value":"20.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.001","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.91","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.86","ciUpperLimit":"0.96","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, Any Revascularization, or UH-VCIN Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, any revascularization, or UH-VCIN. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, any revascularization procedure, or UH-VCIN within 3 years from randomization.","populationDescription":"ITT Population, defined as all participants who were randomly assigned to a treatment arm.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13224"},{"groupId":"OG001","value":"13225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1"},{"groupId":"OG001","value":"19.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.90","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.85","ciUpperLimit":"0.95","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death Within 3 Years From Randomization","description":"The time (in days) from study start to CV death (if reported) was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death within 3 years from randomization.","populationDescription":"ITT Population, defined as all participants who were randomly assigned to a treatment arm.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13224"},{"groupId":"OG001","value":"13225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0"},{"groupId":"OG001","value":"2.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.151","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.89","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.76","ciUpperLimit":"1.04","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced an MI Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of an MI was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced an MI within 3 years from randomization.","populationDescription":"ITT Population, defined as all participants who were randomly assigned to a treatment arm.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13224"},{"groupId":"OG001","value":"13225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1"},{"groupId":"OG001","value":"5.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.001","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.83","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.74","ciUpperLimit":"0.93","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced UCR Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of UCR was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced UCR within 3 years from randomization.","populationDescription":"ITT Population, defined as all participants who were randomly assigned to a treatment arm.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13224"},{"groupId":"OG001","value":"13225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6"},{"groupId":"OG001","value":"2.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.108","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.88","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.75","ciUpperLimit":"1.03","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced a Stroke Within 3 Years From Randomization","description":"The time (in days) from study start to first experience of a stroke was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced a stroke within 3 years from randomization.","populationDescription":"ITT Population, defined as all participants who were randomly assigned to a treatment arm.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13224"},{"groupId":"OG001","value":"13225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8"},{"groupId":"OG001","value":"2.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.733","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.83","ciUpperLimit":"1.14","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Died From Any Cause Within 3 Years From Randomization","description":"The time (in days) from study start to death from any cause was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who died from any cause within 3 years from randomization.","populationDescription":"ITT Population, defined as all participants who were randomly assigned to a treatment arm.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13224"},{"groupId":"OG001","value":"13225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3"},{"groupId":"OG001","value":"5.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.411","statisticalMethod":"Cox Proportional Hazards Regression","paramType":"Cox Proportional Hazard","paramValue":"0.95","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.85","ciUpperLimit":"1.07","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Had a UH-VCIN Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of an UH-VCIN was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who had a UH-VCIN within 3 years from randomization.","populationDescription":"ITT Population, defined as all participants who were randomly assigned to a treatment arm.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13224"},{"groupId":"OG001","value":"13225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5"},{"groupId":"OG001","value":"4.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.001","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.83","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.74","ciUpperLimit":"0.93","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Had Any Revascularization Performed Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of a revascularization was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who had any revascularization performed within 3 years from randomization.","populationDescription":"ITT Population, defined as all participants who were randomly assigned to a treatment arm.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13224"},{"groupId":"OG001","value":"13225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5"},{"groupId":"OG001","value":"13.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.89","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.83","ciUpperLimit":"0.95","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"POST_HOC","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, or UCR Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, or UCR within 3 years from randomization.","populationDescription":"Intended Label Population: all enrolled participants with coronary arterial disease (CAD) or peripheral arterial disease (PAD) and no history of a stroke or transient ischemic attack (TIA)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10090"},{"groupId":"OG001","value":"10080"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8"},{"groupId":"OG001","value":"10.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.83","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.76","ciUpperLimit":"0.90","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"POST_HOC","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, or Stroke Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, or stroke. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, or stroke within 3 years from randomization.","populationDescription":"Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10090"},{"groupId":"OG001","value":"10080"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5"},{"groupId":"OG001","value":"7.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.80","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.73","ciUpperLimit":"0.89","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"POST_HOC","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Met GUSTO Moderate or Severe Bleeding Criteria Within 3 Years From Randomization","description":"Adverse events were categorized as \"bleeding events\" if the intensity, frequency, or type of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the GUSTO cooperative group criteria as follows: Mild , Moderate or Severe and the grading was adjudicated by the CEC. The Kaplan-Meier estimate reports the percentage of participants who experienced GUSTO moderate or severe bleeding within 3 years from randomization.","populationDescription":"Intended Label Safety Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA who received at least 1 dose of study drug","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10049"},{"groupId":"OG001","value":"10059"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7"},{"groupId":"OG001","value":"3.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"1.45","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.23","ciUpperLimit":"1.71","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"POST_HOC","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Clinically Significant Bleeding Within 3 Years From Randomization","description":"Adverse events were categorized as \"bleeding events\" if the intensity, frequency, or type of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the TIMI Study Group criteria as major, minor or other. \"Clinically Significant Bleeding\" was defined as the composite of TIMI Major bleeding, TIMI Minor bleeding, or bleeding that required unplanned medical or surgical treatment or unplanned laboratory evaluation even if it did not meet the criteria for TIMI major or minor bleeding. The Kaplan-Meier estimate reports the percentage of participants who experienced clinically significant bleeding within 3 years from randomization.","populationDescription":"Intended Label Safety Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA who received at least 1 dose of study drug","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10049"},{"groupId":"OG001","value":"10059"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"15.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"1.42","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.31","ciUpperLimit":"1.54","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"POST_HOC","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Death From Any Cause, MI, Stroke, or UCR Within 3 Years From Randomization","description":"The time (in days) from study start to the occurrence of any of the following clinical outcomes was recorded: death from any cause, MI, stroke, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who experienced death from any cause, MI, stroke, or UCR within 3 years from randomization.","populationDescription":"Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10090"},{"groupId":"OG001","value":"10080"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5"},{"groupId":"OG001","value":"11.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.79","ciUpperLimit":"0.93","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"POST_HOC","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death or an MI Within 3 Years From Randomization","description":"The time (in days) from study start to the occurrence of CV death or first occurrence of an MI. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death or MI within 3 years from randomization.","populationDescription":"Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Partcipants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10090"},{"groupId":"OG001","value":"10080"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3"},{"groupId":"OG001","value":"7.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.83","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.75","ciUpperLimit":"0.93","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"POST_HOC","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, UCR, or UH-VCIN Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, UCR, or UH-VCIN . A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, UCR, or UH-VCIN within 3 years from randomization.","populationDescription":"Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10090"},{"groupId":"OG001","value":"10080"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.9"},{"groupId":"OG001","value":"11.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.83","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.77","ciUpperLimit":"0.90","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"POST_HOC","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Died From Any Cause, or Experienced an MI, Stroke, or Any Revascularization Within 3 Years From Randomization","description":"The time (in days) from study start to death from any cause or the first occurrence of any of the following clinical outcomes was recorded: MI, stroke, or any revascularization procedure . A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who died from any cause, or experienced an MI, stroke, or any revascularization within 3 years from randomization.","populationDescription":"Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10090"},{"groupId":"OG001","value":"10080"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.5"},{"groupId":"OG001","value":"20.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.89","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.83","ciUpperLimit":"0.95","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"POST_HOC","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, Any Revascularization, or UH-VCIN Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, any revascularization, or UH-VCIN. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, any revascularization procedure, or UH-VCIN within 3 years from randomization.","populationDescription":"Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10090"},{"groupId":"OG001","value":"10080"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.8"},{"groupId":"OG001","value":"19.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.88","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.83","ciUpperLimit":"0.94","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"POST_HOC","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death Within 3 Years From Randomization","description":"The time (in days) from study start to the CV death (if reported) was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death within 3 years from randomization.","populationDescription":"Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10090"},{"groupId":"OG001","value":"10080"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8"},{"groupId":"OG001","value":"2.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.108","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.71","ciUpperLimit":"1.03","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"POST_HOC","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced an MI Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of an MI was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced an MI within 3 years from randomization.","populationDescription":"Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10090"},{"groupId":"OG001","value":"10080"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4"},{"groupId":"OG001","value":"5.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.002","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.82","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.73","ciUpperLimit":"0.93","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"POST_HOC","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced UCR Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of UCR was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced UCR within 3 years from randomization.","populationDescription":"Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10090"},{"groupId":"OG001","value":"10080"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0"},{"groupId":"OG001","value":"2.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.127","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.88","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.74","ciUpperLimit":"1.04","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"POST_HOC","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Experienced a Stroke Within 3 Years From Randomization","description":"The time (in days) from study start to first experience of a stroke was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced a stroke within 3 years from randomization.","populationDescription":"Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10090"},{"groupId":"OG001","value":"10080"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6"},{"groupId":"OG001","value":"1.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.002","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.67","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.52","ciUpperLimit":"0.87","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"POST_HOC","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Died From Any Cause Within 3 Years From Randomization","description":"The time (in days) from study start to death from any cause was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who died from any cause within 3 years from randomization.","populationDescription":"Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10090"},{"groupId":"OG001","value":"10080"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8"},{"groupId":"OG001","value":"4.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.249","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.92","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.80","ciUpperLimit":"1.06","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"POST_HOC","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Had a UH-VCIN Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of a UH-VCIN was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who had a UH-VCIN within 3 years from randomization.","populationDescription":"Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10090"},{"groupId":"OG001","value":"10080"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"4.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.019","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.76","ciUpperLimit":"0.98","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]},{"type":"POST_HOC","title":"Kaplan-Meier Estimate of the Percentage of Participants Who Had Any Revascularization Performed Within 3 Years From Randomization","description":"The time (in days) from study start to the first occurrence of any revascularization was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who had any revascularization performed within 3 years from randomization.","populationDescription":"Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"up to 3 years","groups":[{"id":"OG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."},{"id":"OG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10090"},{"groupId":"OG001","value":"10080"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6"},{"groupId":"OG001","value":"14.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.003","statisticalMethod":"Cox Proportional Hazards Regression","statisticalComment":"Hazard Ratio calculated with covariates for treatment and stratification factors","paramType":"Cox Proportional Hazard","paramValue":"0.89","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.83","ciUpperLimit":"0.96","estimateComment":"Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio \\<1 would indicate a lower hazard associated with vorapaxar relative to placebo."}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"up to 3 years","description":"Adverse events are reported using the As Treated Population, which included all participants who received at least 1 dose of study medication and are reported according to treatment received","eventGroups":[{"id":"EG000","title":"Placebo","description":"1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.","seriousNumAffected":3419,"seriousNumAtRisk":13166,"otherNumAffected":2280,"otherNumAtRisk":13166},{"id":"EG001","title":"Vorapaxar","description":"one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.","seriousNumAffected":3514,"seriousNumAtRisk":13186,"otherNumAffected":2541,"otherNumAtRisk":13186}],"seriousEvents":[{"term":"ANAEMIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":13166},{"groupId":"EG001","numEvents":47,"numAffected":45,"numAtRisk":13186}]},{"term":"ANAEMIA HAEMOLYTIC AUTOIMMUNE","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ANAEMIA OF CHRONIC DISEASE","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"APLASIA PURE RED CELL","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"AUTOIMMUNE THROMBOCYTOPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"COAGULOPATHY","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"FEBRILE NEUTROPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HAEMORRHAGIC ANAEMIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HAEMORRHAGIC DIATHESIS","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"HEPARIN-INDUCED THROMBOCYTOPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"IDIOPATHIC THROMBOCYTOPENIC PURPURA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"IRON DEFICIENCY ANAEMIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":13186}]},{"term":"LEUKOCYTOSIS","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"LEUKOPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"LYMPHADENOPATHY","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"MICROCYTIC ANAEMIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"NEPHROGENIC ANAEMIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"NEUTROPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"NORMOCHROMIC NORMOCYTIC ANAEMIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"PANCYTOPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"PERNICIOUS ANAEMIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"RETROPERITONEAL LYMPHADENOPATHY","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SPLENIC HAEMORRHAGE","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"THROMBOCYTOPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":23,"numAtRisk":13166},{"groupId":"EG001","numEvents":20,"numAffected":19,"numAtRisk":13186}]},{"term":"THROMBOCYTOSIS","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"THROMBOTIC THROMBOCYTOPENIC PURPURA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ACUTE CORONARY SYNDROME","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ADAMS-STOKES SYNDROME","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ANGINA PECTORIS","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"AORTIC VALVE INCOMPETENCE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"AORTIC VALVE STENOSIS","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":13186}]},{"term":"ARRHYTHMIA","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"ARRHYTHMIA SUPRAVENTRICULAR","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ATRIAL FIBRILLATION","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":118,"numAffected":106,"numAtRisk":13166},{"groupId":"EG001","numEvents":156,"numAffected":137,"numAtRisk":13186}]},{"term":"ATRIAL FLUTTER","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":18,"numAtRisk":13166},{"groupId":"EG001","numEvents":28,"numAffected":28,"numAtRisk":13186}]},{"term":"ATRIAL TACHYCARDIA","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ATRIAL THROMBOSIS","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"ATRIOVENTRICULAR BLOCK","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"ATRIOVENTRICULAR BLOCK COMPLETE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":13166},{"groupId":"EG001","numEvents":19,"numAffected":19,"numAtRisk":13186}]},{"term":"ATRIOVENTRICULAR BLOCK FIRST DEGREE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ATRIOVENTRICULAR BLOCK SECOND DEGREE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"BIFASCICULAR BLOCK","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BRADYCARDIA","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":27,"numAtRisk":13166},{"groupId":"EG001","numEvents":20,"numAffected":20,"numAtRisk":13186}]},{"term":"BUNDLE BRANCH BLOCK LEFT","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BUNDLE BRANCH BLOCK RIGHT","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"CARDIAC ANEURYSM","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"CARDIAC ARREST","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"CARDIAC ASTHMA","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"CARDIAC FAILURE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":222,"numAffected":174,"numAtRisk":13166},{"groupId":"EG001","numEvents":245,"numAffected":183,"numAtRisk":13186}]},{"term":"CARDIAC FAILURE ACUTE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":13186}]},{"term":"CARDIAC FAILURE CHRONIC","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CARDIAC FAILURE CONGESTIVE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":99,"numAffected":82,"numAtRisk":13166},{"groupId":"EG001","numEvents":121,"numAffected":95,"numAtRisk":13186}]},{"term":"CARDIAC TAMPONADE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":13186}]},{"term":"CARDIO-RESPIRATORY ARREST","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"CARDIOGENIC SHOCK","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":13166},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":13186}]},{"term":"CARDIOMYOPATHY","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"CARDIOPULMONARY FAILURE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"CHRONOTROPIC INCOMPETENCE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"CONDUCTION DISORDER","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"CONGESTIVE CARDIOMYOPATHY","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"CORONARY ARTERY DISEASE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"DRESSLER'S SYNDROME","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":13186}]},{"term":"EXTRASYSTOLES","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HEART VALVE INCOMPETENCE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HYPERTENSIVE HEART DISEASE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"INTRACARDIAC THROMBUS","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ISCHAEMIC CARDIOMYOPATHY","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":13166},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":13186}]},{"term":"LEFT VENTRICULAR DYSFUNCTION","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":13186}]},{"term":"LEFT VENTRICULAR FAILURE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"MITRAL VALVE INCOMPETENCE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"MITRAL VALVE PROLAPSE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MITRAL VALVE STENOSIS","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"MYOCARDIAL RUPTURE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MYOPERICARDITIS","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"NODAL ARRHYTHMIA","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"PALPITATIONS","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"PERICARDIAL EFFUSION","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"PERICARDIAL HAEMORRHAGE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":13186}]},{"term":"PERICARDITIS","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"PULSELESS ELECTRICAL ACTIVITY","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"SICK SINUS SYNDROME","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":20,"numAtRisk":13166},{"groupId":"EG001","numEvents":22,"numAffected":20,"numAtRisk":13186}]},{"term":"SINUS ARREST","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SINUS ARRHYTHMIA","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"SINUS BRADYCARDIA","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"SINUS TACHYCARDIA","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"STRESS CARDIOMYOPATHY","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":13186}]},{"term":"SUPRAVENTRICULAR EXTRASYSTOLES","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SUPRAVENTRICULAR TACHYCARDIA","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":16,"numAtRisk":13166},{"groupId":"EG001","numEvents":14,"numAffected":13,"numAtRisk":13186}]},{"term":"TACHYARRHYTHMIA","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"TACHYCARDIA","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"TORSADE DE POINTES","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"VENTRICULAR ARRHYTHMIA","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"VENTRICULAR ASYSTOLE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"VENTRICULAR DYSFUNCTION","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"VENTRICULAR DYSSYNCHRONY","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"VENTRICULAR EXTRASYSTOLES","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"VENTRICULAR FIBRILLATION","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":15,"numAtRisk":13166},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":13186}]},{"term":"VENTRICULAR TACHYCARDIA","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":37,"numAtRisk":13166},{"groupId":"EG001","numEvents":42,"numAffected":37,"numAtRisk":13186}]},{"term":"ARTERIOVENOUS MALFORMATION","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ATRIAL SEPTAL DEFECT","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"EPIDERMOLYSIS","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"GASTROINTESTINAL ANGIODYSPLASIA","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"GASTROINTESTINAL ANGIODYSPLASIA HAEMORRHAGIC","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GASTROINTESTINAL ARTERIOVENOUS MALFORMATION","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HAEMORRHAGIC ARTERIOVENOUS MALFORMATION","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HIP DYSPLASIA","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HYDROCELE","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PHIMOSIS","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PORPHYRIA","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PYLORIC STENOSIS","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"VENTRICULAR SEPTAL DEFECT","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ACUTE VESTIBULAR SYNDROME","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"DEAFNESS","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HYPOACUSIS","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"MENIERE'S DISEASE","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SUDDEN HEARING LOSS","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"VERTIGO","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":16,"numAtRisk":13166},{"groupId":"EG001","numEvents":24,"numAffected":23,"numAtRisk":13186}]},{"term":"VERTIGO POSITIONAL","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"VESTIBULAR DISORDER","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"ADDISON'S DISEASE","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ADRENAL MASS","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"AUTOIMMUNE THYROIDITIS","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BASEDOW'S DISEASE","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GOITRE","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HYPERCALCAEMIA OF MALIGNANCY","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HYPERPARATHYROIDISM","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HYPERTHYROIDISM","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"HYPOTHYROIDISM","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"AMAUROSIS","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BLINDNESS UNILATERAL","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"CATARACT","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":15,"numAtRisk":13166},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":13186}]},{"term":"CONJUNCTIVAL HAEMORRHAGE","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"CORNEAL OEDEMA","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"DIABETIC RETINOPATHY","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":13186}]},{"term":"ENDOCRINE OPHTHALMOPATHY","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"EYE HAEMORRHAGE","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"GLAUCOMA","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HYPHAEMA","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LACRIMATION INCREASED","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MACULAR DEGENERATION","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MACULAR FIBROSIS","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MACULAR HOLE","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"OCULAR HYPERTENSION","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"OPTIC ISCHAEMIC NEUROPATHY","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"OPTIC NEUROPATHY","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"POSTERIOR CAPSULE OPACIFICATION","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"RETINAL ARTERY THROMBOSIS","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"RETINAL DETACHMENT","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"RETINAL VEIN OCCLUSION","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"RETINAL VEIN THROMBOSIS","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ULCERATIVE KERATITIS","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"VISION BLURRED","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"VISUAL IMPAIRMENT","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"VITREOUS HAEMORRHAGE","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ABDOMINAL ADHESIONS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"ABDOMINAL COMPARTMENT SYNDROME","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ABDOMINAL DISCOMFORT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ABDOMINAL HERNIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"ABDOMINAL HERNIA OBSTRUCTIVE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ABDOMINAL MASS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ABDOMINAL PAIN","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":17,"numAtRisk":13166},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":13186}]},{"term":"ABDOMINAL PAIN LOWER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ABDOMINAL PAIN UPPER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":13166},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":13186}]},{"term":"ABDOMINAL WALL HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ACUTE ABDOMEN","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ANAL FISTULA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"ANAL HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"ASCITES","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BARRETT'S OESOPHAGUS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BUCCAL POLYP","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"COLITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":13166},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":13186}]},{"term":"COLITIS EROSIVE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"COLITIS ISCHAEMIC","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":13166},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":13186}]},{"term":"COLITIS ULCERATIVE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"COLONIC POLYP","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":13186}]},{"term":"COLONIC PSEUDO-OBSTRUCTION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CONSTIPATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":13166},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":13186}]},{"term":"CROHN'S DISEASE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"DENTAL CARIES","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"DENTAL NECROSIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"DIABETIC GASTROPARESIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"DIARRHOEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":13186}]},{"term":"DIARRHOEA HAEMORRHAGIC","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"DIVERTICULAR PERFORATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"DIVERTICULITIS INTESTINAL HAEMORRHAGIC","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"DIVERTICULUM","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"DIVERTICULUM INTESTINAL","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"DIVERTICULUM INTESTINAL HAEMORRHAGIC","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":13186}]},{"term":"DIVERTICULUM OESOPHAGEAL","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"DUODENAL PERFORATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"DUODENAL ULCER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":13186}]},{"term":"DUODENAL ULCER HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"DUODENITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"DYSPEPSIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":13186}]},{"term":"DYSPHAGIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"ENTERITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"ENTEROCELE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ENTEROCOLITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ENTEROCOLITIS HAEMORRHAGIC","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ENTEROVESICAL FISTULA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"EPIGASTRIC DISCOMFORT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"EPIPLOIC APPENDAGITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"EROSIVE DUODENITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"EROSIVE OESOPHAGITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"FAECALOMA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"FAECES DISCOLOURED","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"FEMORAL HERNIA, OBSTRUCTIVE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"FOOD POISONING","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"FUNCTIONAL GASTROINTESTINAL DISORDER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GASTRIC DISORDER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GASTRIC HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"GASTRIC PERFORATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GASTRIC ULCER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":13186}]},{"term":"GASTRIC ULCER HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"GASTRIC ULCER PERFORATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"GASTRIC VOLVULUS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GASTRITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":29,"numAtRisk":13166},{"groupId":"EG001","numEvents":26,"numAffected":26,"numAtRisk":13186}]},{"term":"GASTRITIS ALCOHOLIC","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"GASTRITIS ATROPHIC","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GASTRITIS EROSIVE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":13186}]},{"term":"GASTRODUODENAL ULCER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GASTROINTESTINAL DISORDER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GASTROINTESTINAL HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":38,"numAtRisk":13166},{"groupId":"EG001","numEvents":70,"numAffected":62,"numAtRisk":13186}]},{"term":"GASTROINTESTINAL INFLAMMATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"GASTROINTESTINAL NECROSIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"GASTROINTESTINAL OBSTRUCTION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GASTROINTESTINAL TELANGIECTASIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"GASTROINTESTINAL ULCER HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"GASTROOESOPHAGEAL REFLUX DISEASE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":31,"numAtRisk":13166},{"groupId":"EG001","numEvents":24,"numAffected":23,"numAtRisk":13186}]},{"term":"GINGIVAL BLEEDING","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"HAEMATEMESIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":19,"numAtRisk":13166},{"groupId":"EG001","numEvents":28,"numAffected":28,"numAtRisk":13186}]},{"term":"HAEMATOCHEZIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":21,"numAtRisk":13166},{"groupId":"EG001","numEvents":18,"numAffected":16,"numAtRisk":13186}]},{"term":"HAEMORRHOIDAL HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"HAEMORRHOIDS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"HERNIAL EVENTRATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HIATUS HERNIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"ILEAL STENOSIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ILEUS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":10,"numAffected":8,"numAtRisk":13186}]},{"term":"IMPAIRED GASTRIC EMPTYING","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"INFLAMMATORY BOWEL DISEASE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"INGUINAL HERNIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":35,"numAtRisk":13166},{"groupId":"EG001","numEvents":44,"numAffected":42,"numAtRisk":13186}]},{"term":"INGUINAL HERNIA STRANGULATED","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"INGUINAL HERNIA, OBSTRUCTIVE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"INTESTINAL ISCHAEMIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"INTESTINAL MASS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"INTESTINAL OBSTRUCTION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":13166},{"groupId":"EG001","numEvents":14,"numAffected":13,"numAtRisk":13186}]},{"term":"INTESTINAL PERFORATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"INTESTINAL POLYP","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"INTESTINAL STRANGULATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"JEJUNAL PERFORATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LARGE INTESTINAL HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LARGE INTESTINAL OBSTRUCTION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LARGE INTESTINAL ULCER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LARGE INTESTINAL ULCER HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LARGE INTESTINE PERFORATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"LOWER GASTROINTESTINAL HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":13186}]},{"term":"LUMBAR HERNIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MALABSORPTION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MALLORY-WEISS SYNDROME","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"MECHANICAL ILEUS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MELAENA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":44,"numAtRisk":13166},{"groupId":"EG001","numEvents":76,"numAffected":69,"numAtRisk":13186}]},{"term":"MESENTERIC ARTERY STENOSIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MESENTERIC ARTERY THROMBOSIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MESENTERIC VASCULAR INSUFFICIENCY","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MOUTH CYST","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"NAUSEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":13186}]},{"term":"OESOPHAGEAL ACHALASIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"OESOPHAGEAL HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"OESOPHAGEAL OBSTRUCTION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"OESOPHAGEAL RUPTURE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"OESOPHAGEAL SPASM","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"OESOPHAGEAL STENOSIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"OESOPHAGEAL ULCER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"OESOPHAGEAL ULCER HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"OESOPHAGITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":13186}]},{"term":"PANCREATIC CYST","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PANCREATIC DISORDER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PANCREATITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":17,"numAtRisk":13166},{"groupId":"EG001","numEvents":18,"numAffected":17,"numAtRisk":13186}]},{"term":"PANCREATITIS ACUTE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":11,"numAtRisk":13166},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":13186}]},{"term":"PANCREATITIS RELAPSING","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PAPILLA OF VATER STENOSIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PAROTID GLAND ENLARGEMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PEPTIC ULCER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":13186}]},{"term":"PEPTIC ULCER HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"PERITONEAL HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"PHARYNGOESOPHAGEAL DIVERTICULUM","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"POLYP COLORECTAL","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PROCTITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PROCTITIS HAEMORRHAGIC","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PROCTITIS ULCERATIVE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"RECTAL HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":41,"numAffected":37,"numAtRisk":13166},{"groupId":"EG001","numEvents":59,"numAffected":53,"numAtRisk":13186}]},{"term":"RECTAL PROLAPSE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"RECTAL ULCER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"RETROPERITONEAL HAEMATOMA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"RETROPERITONEAL HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":13186}]},{"term":"SALIVARY GLAND CALCULUS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SMALL INTESTINAL HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"SMALL INTESTINAL OBSTRUCTION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":14,"numAtRisk":13166},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":13186}]},{"term":"SMALL INTESTINAL PERFORATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SPIGELIAN HERNIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SPLENIC ARTERY ANEURYSM","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SUBILEUS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"THROMBOSIS MESENTERIC VESSEL","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"TONGUE HAEMATOMA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"TONGUE OEDEMA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"UMBILICAL HERNIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"UMBILICAL HERNIA, OBSTRUCTIVE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"UPPER GASTROINTESTINAL HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":17,"numAtRisk":13166},{"groupId":"EG001","numEvents":16,"numAffected":15,"numAtRisk":13186}]},{"term":"VARICES OESOPHAGEAL","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"VOMITING","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ADVERSE DRUG REACTION","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":13166},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":13186}]},{"term":"APPLICATION SITE BLEEDING","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ASTHENIA","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CATHETER SITE HAEMATOMA","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":13186}]},{"term":"CATHETER SITE HAEMORRHAGE","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":13186}]},{"term":"CHEST DISCOMFORT","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"CHEST PAIN","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":14,"numAtRisk":13166},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":13186}]},{"term":"CYST","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CYST RUPTURE","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"DEVICE BREAKAGE","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"DEVICE DISLOCATION","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":13186}]},{"term":"DEVICE FAILURE","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"DEVICE LEAD DAMAGE","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"DEVICE MALFUNCTION","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"DEVICE OCCLUSION","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"DISCOMFORT","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"DRUG INTERACTION","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"EXERCISE TOLERANCE DECREASED","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"FATIGUE","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"GAIT DISTURBANCE","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"GENERAL PHYSICAL HEALTH DETERIORATION","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GRAVITATIONAL OEDEMA","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HERNIA","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":13186}]},{"term":"HERNIA OBSTRUCTIVE","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"HYPERPLASIA","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HYPERTROPHY","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HYPOTHERMIA","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ILL-DEFINED DISORDER","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"IMPAIRED HEALING","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"IMPLANT SITE EROSION","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"IMPLANT SITE PAIN","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"INFLAMMATION","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MALAISE","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MEDICAL DEVICE COMPLICATION","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MUCOSAL INFLAMMATION","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MULTI-ORGAN DISORDER","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"MULTI-ORGAN FAILURE","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"NECROSIS","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"NODULE","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"NON-CARDIAC CHEST PAIN","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":548,"numAffected":458,"numAtRisk":13166},{"groupId":"EG001","numEvents":519,"numAffected":443,"numAtRisk":13186}]},{"term":"OEDEMA","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"OEDEMA PERIPHERAL","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"PAIN","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PERFORATED ULCER","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"POLYP","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"POLYSEROSITIS","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PYREXIA","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":13166},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":13186}]},{"term":"SYSTEMIC INFLAMMATORY RESPONSE SYNDROME","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"THROMBOSIS IN DEVICE","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ULCER","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ULCER HAEMORRHAGE","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BILE DUCT OBSTRUCTION","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BILE DUCT STONE","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"BILIARY COLIC","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"BILIARY DILATATION","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BILIARY DYSKINESIA","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"CHOLANGITIS","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"CHOLANGITIS ACUTE","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"CHOLECYSTITIS","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":26,"numAtRisk":13166},{"groupId":"EG001","numEvents":32,"numAffected":31,"numAtRisk":13186}]},{"term":"CHOLECYSTITIS ACUTE","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":18,"numAtRisk":13166},{"groupId":"EG001","numEvents":18,"numAffected":18,"numAtRisk":13186}]},{"term":"CHOLECYSTITIS CHRONIC","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"CHOLELITHIASIS","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":42,"numAtRisk":13166},{"groupId":"EG001","numEvents":43,"numAffected":42,"numAtRisk":13186}]},{"term":"CHOLESTASIS","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"GALLBLADDER DISORDER","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"GALLBLADDER POLYP","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HEPATIC CIRRHOSIS","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HEPATIC FAILURE","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"HEPATIC MASS","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HEPATIC STEATOSIS","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HEPATITIS","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HEPATITIS ACUTE","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HEPATITIS TOXIC","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HEPATORENAL SYNDROME","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HEPATOTOXICITY","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ISCHAEMIC HEPATITIS","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LIVER DISORDER","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ALLERGY TO ARTHROPOD STING","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ANAPHYLACTIC REACTION","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"ANAPHYLACTIC SHOCK","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"DRUG HYPERSENSITIVITY","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"FOOD ALLERGY","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HYPERSENSITIVITY","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HYPOGAMMAGLOBULINAEMIA","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ABDOMINAL ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"ABDOMINAL WALL ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ABSCESS INTESTINAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ABSCESS LIMB","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"ABSCESS ORAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ANAL ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":13186}]},{"term":"APPENDICEAL ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"APPENDICITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":23,"numAtRisk":13166},{"groupId":"EG001","numEvents":20,"numAffected":20,"numAtRisk":13186}]},{"term":"ARTERIOVENOUS FISTULA SITE INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ARTERIOVENOUS GRAFT SITE ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ARTERIOVENOUS GRAFT SITE INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ARTHRITIS BACTERIAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"ARTHRITIS INFECTIVE","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ASPERGILLOMA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BACTERAEMIA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"BACTERIAL INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"BACTERIAL PROSTATITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BILIARY SEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BLASTOCYSTIS INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BORRELIA INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BRONCHIOLITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BRONCHITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":29,"numAtRisk":13166},{"groupId":"EG001","numEvents":27,"numAffected":27,"numAtRisk":13186}]},{"term":"BRONCHITIS BACTERIAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BRONCHOPNEUMONIA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":13166},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":13186}]},{"term":"BURSITIS INFECTIVE","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"CAMPYLOBACTER GASTROENTERITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"CAMPYLOBACTER INTESTINAL INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"CARDIAC INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CELLULITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":41,"numAffected":38,"numAtRisk":13166},{"groupId":"EG001","numEvents":45,"numAffected":42,"numAtRisk":13186}]},{"term":"CELLULITIS OF MALE EXTERNAL GENITAL ORGAN","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CENTRAL NERVOUS SYSTEM INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CHOLECYSTITIS INFECTIVE","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"CHRONIC SINUSITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"CLOSTRIDIAL INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"CLOSTRIDIUM COLITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CLOSTRIDIUM DIFFICILE COLITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":16,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"COCCIDIOIDOMYCOSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CYSTITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"CYTOMEGALOVIRUS INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"DENGUE FEVER","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"DEVICE RELATED INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":13186}]},{"term":"DEVICE RELATED SEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"DIABETIC FOOT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"DIABETIC GANGRENE","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"DISSEMINATED TUBERCULOSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"DIVERTICULITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":20,"numAtRisk":13166},{"groupId":"EG001","numEvents":17,"numAffected":16,"numAtRisk":13186}]},{"term":"DYSENTERY","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"EAR INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ECZEMA INFECTED","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"EMPYEMA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ENCEPHALITIS HERPES","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ENDOCARDITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"ENDOPHTHALMITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ENTERITIS INFECTIOUS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ENTEROBACTER INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ENTEROCOLITIS INFECTIOUS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"EPIDEMIC NEPHROPATHY","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"EPIGLOTTITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ERYSIPELAS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":18,"numAtRisk":13166},{"groupId":"EG001","numEvents":15,"numAffected":14,"numAtRisk":13186}]},{"term":"ESCHERICHIA BACTERAEMIA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ESCHERICHIA INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ESCHERICHIA SEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"ESCHERICHIA URINARY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"EYE ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"FUNGAEMIA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GANGRENE","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GASTRIC INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"GASTROENTERITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":37,"numAtRisk":13166},{"groupId":"EG001","numEvents":37,"numAffected":36,"numAtRisk":13186}]},{"term":"GASTROENTERITIS ESCHERICHIA COLI","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"GASTROENTERITIS NOROVIRUS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GASTROENTERITIS VIRAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"GASTROINTESTINAL BACTERIAL INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"GASTROINTESTINAL VIRAL INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GINGIVAL ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GRAFT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":13186}]},{"term":"GROIN ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"GROIN INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"H1N1 INFLUENZA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"HAEMATOMA INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HELICOBACTER INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HEPATITIS B","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HEPATITIS C","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HERPES SIMPLEX","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HERPES ZOSTER","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"HISTOPLASMOSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HIV INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"IMPLANT SITE INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"INCISION SITE INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"INFECTED BITES","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"INFECTED DERMAL CYST","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"INFECTED SKIN ULCER","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":13166},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":13186}]},{"term":"INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"INFECTIOUS PERITONITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"INFECTIOUS PLEURAL EFFUSION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"INFLUENZA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"INFUSION SITE INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LABYRINTHITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"LIVER ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LOBAR PNEUMONIA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":20,"numAtRisk":13166},{"groupId":"EG001","numEvents":23,"numAffected":23,"numAtRisk":13186}]},{"term":"LOCALISED INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":13166},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":13186}]},{"term":"LOWER RESPIRATORY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"LOWER RESPIRATORY TRACT INFECTION VIRAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LUNG ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LUNG INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"LYME DISEASE","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LYMPHANGITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MASTOIDITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MEDIASTINITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MENINGITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MENINGITIS ASEPTIC","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MENINGITIS BACTERIAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MENINGITIS VIRAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MYCOBACTERIUM AVIUM COMPLEX INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"NECROTISING FASCIITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"OESOPHAGEAL CANDIDIASIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"ONYCHOMYCOSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ORAL CANDIDIASIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ORAL INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ORCHITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"OSTEOMYELITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":17,"numAtRisk":13166},{"groupId":"EG001","numEvents":16,"numAffected":14,"numAtRisk":13186}]},{"term":"OSTEOMYELITIS CHRONIC","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"OTITIS EXTERNA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"OTITIS MEDIA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"OTITIS MEDIA CHRONIC","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PAROTITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PERICARDITIS INFECTIVE","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":13186}]},{"term":"PERIDIVERTICULAR ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PERINEAL ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PERINEPHRIC ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PERIORBITAL CELLULITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PERIRECTAL ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PERITONSILLAR ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PHARYNGITIS BACTERIAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PILONIDAL CYST","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PNEUMOCYSTIS JIROVECI PNEUMONIA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PNEUMONIA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":205,"numAffected":186,"numAtRisk":13166},{"groupId":"EG001","numEvents":185,"numAffected":167,"numAtRisk":13186}]},{"term":"PNEUMONIA BACTERIAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"PNEUMONIA ESCHERICHIA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PNEUMONIA FUNGAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PNEUMONIA MYCOPLASMAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"PNEUMONIA PNEUMOCOCCAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"PNEUMONIA STAPHYLOCOCCAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"PNEUMONIA VIRAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"POST PROCEDURAL CELLULITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"POST PROCEDURAL INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"POST PROCEDURAL SEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"POSTOPERATIVE ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"POSTOPERATIVE WOUND INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":21,"numAtRisk":13166},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":13186}]},{"term":"PSEUDOMEMBRANOUS COLITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PSOAS ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PULMONARY SEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":13166},{"groupId":"EG001","numEvents":18,"numAffected":18,"numAtRisk":13186}]},{"term":"PULMONARY TUBERCULOSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PYELONEPHRITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":13166},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":13186}]},{"term":"PYELONEPHRITIS ACUTE","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"RECTAL ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"RESPIRATORY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"RESPIRATORY TRACT INFECTION VIRAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SALMONELLA SEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SALMONELLOSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SCROTAL ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":34,"numAtRisk":13166},{"groupId":"EG001","numEvents":29,"numAffected":28,"numAtRisk":13186}]},{"term":"SEPTIC NECROSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SEPTIC SHOCK","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":22,"numAtRisk":13166},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":13186}]},{"term":"SERRATIA INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SIALOADENITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SINUSITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"SINUSITIS BACTERIAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SKIN INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SOFT TISSUE INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"STAPHYLOCOCCAL ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"STAPHYLOCOCCAL BACTERAEMIA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"STAPHYLOCOCCAL INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"STAPHYLOCOCCAL SEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SUBCUTANEOUS ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"SUPERINFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SYPHILIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SYSTEMIC CANDIDA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"TONSILLITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"TOOTH ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"TUBERCULOSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"TYPHUS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"UPPER RESPIRATORY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"URINARY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":53,"numAffected":50,"numAtRisk":13166},{"groupId":"EG001","numEvents":67,"numAffected":62,"numAtRisk":13186}]},{"term":"URINARY TRACT INFECTION BACTERIAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"URINARY TRACT INFECTION PSEUDOMONAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"URINARY TRACT INFECTION STAPHYLOCOCCAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"UROSEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":13166},{"groupId":"EG001","numEvents":27,"numAffected":27,"numAtRisk":13186}]},{"term":"VAGINAL INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"VARICELLA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"VESTIBULAR NEURONITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"VIRAL INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":13166},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":13186}]},{"term":"VIRAL LABYRINTHITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"VIRAL MYOCARDITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"VIRAL UPPER RESPIRATORY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"WOUND ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"WOUND INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":13186}]},{"term":"WOUND INFECTION PSEUDOMONAS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"WOUND INFECTION STAPHYLOCOCCAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"WOUND SEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ABDOMINAL WOUND DEHISCENCE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ACCIDENT","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ACCIDENTAL OVERDOSE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ACETABULUM FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ALCOHOL POISONING","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":13166},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":13186}]},{"term":"ANAEMIA POSTOPERATIVE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"ANASTOMOTIC COMPLICATION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ANASTOMOTIC STENOSIS","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":13186}]},{"term":"ANKLE FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":15,"numAtRisk":13166},{"groupId":"EG001","numEvents":18,"numAffected":17,"numAtRisk":13186}]},{"term":"ARTERIAL INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ARTHROPOD BITE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ARTHROPOD STING","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BRAIN CONTUSION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BURNS THIRD DEGREE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"CARBON MONOXIDE POISONING","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":13186}]},{"term":"CARDIAC FUNCTION DISTURBANCE POSTOPERATIVE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"CARTILAGE INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CERVICAL VERTEBRAL FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"CHEMICAL EYE INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CHEST INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"CLAVICLE FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"CONCUSSION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"CONFUSION POSTOPERATIVE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"CONTUSION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":11,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"CRANIOCEREBRAL INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CYSTITIS RADIATION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"EAR INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ELECTRIC SHOCK","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"EXCORIATION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"EXTRADURAL HAEMATOMA","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"FACE INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"FACIAL BONES FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"FALL","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":13166},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":13186}]},{"term":"FEBRILE NONHAEMOLYTIC TRANSFUSION REACTION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"FEMORAL NECK FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"FEMUR FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":22,"numAtRisk":13166},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":13186}]},{"term":"FIBULA FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"FLAIL CHEST","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"FOOT FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"FOREARM FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"FOREIGN BODY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GASTROINTESTINAL STOMA COMPLICATION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"GUN SHOT WOUND","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"HAND FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"HEAD INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":13186}]},{"term":"HEAT EXHAUSTION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HEAT STROKE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HIP FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":19,"numAtRisk":13166},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":13186}]},{"term":"HUMERUS FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":13166},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":13186}]},{"term":"INCISION SITE HAEMORRHAGE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"INCISION SITE PAIN","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"INCISIONAL HERNIA","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"INTERVERTEBRAL DISC INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"JAW FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"JOINT DISLOCATION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":13166},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":13186}]},{"term":"JOINT INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"LACERATION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"LIGAMENT RUPTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LIMB INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":13186}]},{"term":"LIMB TRAUMATIC AMPUTATION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LOWER LIMB FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"LUMBAR VERTEBRAL FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"MENISCUS LESION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"MULTIPLE DRUG OVERDOSE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MULTIPLE FRACTURES","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"MULTIPLE INJURIES","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":13186}]},{"term":"MUSCLE RUPTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"MUSCLE STRAIN","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"NERVE INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"OPEN FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"OPEN WOUND","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"OPERATIVE HAEMORRHAGE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":19,"numAtRisk":13166},{"groupId":"EG001","numEvents":23,"numAffected":23,"numAtRisk":13186}]},{"term":"OVERDOSE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"PATELLA FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PELVIC FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"PERIPROSTHETIC FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"POISONING","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"POST PROCEDURAL COMPLICATION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"POST PROCEDURAL DISCHARGE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"POST PROCEDURAL HAEMATOMA","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"POST PROCEDURAL HAEMORRHAGE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":23,"numAtRisk":13166},{"groupId":"EG001","numEvents":40,"numAffected":39,"numAtRisk":13186}]},{"term":"POSTOPERATIVE ADHESION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"POSTOPERATIVE FEVER","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"POSTOPERATIVE ILEUS","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":13186}]},{"term":"POSTOPERATIVE RESPIRATORY DISTRESS","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"POSTOPERATIVE THORACIC PROCEDURE COMPLICATION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"POSTPERICARDIOTOMY SYNDROME","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"PROCEDURAL HYPOTENSION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PROCEDURAL PAIN","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"PUBIS FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"RADIATION ASSOCIATED PAIN","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"RADIATION INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"RADIATION OESOPHAGITIS","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"RADIUS FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"RIB FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":13166},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":13186}]},{"term":"ROAD TRAFFIC ACCIDENT","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":16,"numAtRisk":13166},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":13186}]},{"term":"SCAPULA FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SEROMA","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SKIN FLAP NECROSIS","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SKULL FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SNAKE BITE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SOFT TISSUE INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SPINAL COLUMN INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SPINAL COMPRESSION FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":13186}]},{"term":"SPINAL FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"SPLENIC RUPTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"STAB WOUND","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"STERNAL FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"STRUCK BY LIGHTNING","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SUBDURAL HAEMATOMA","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":13166},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":13186}]},{"term":"SUBDURAL HAEMORRHAGE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"TENDON RUPTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":13186}]},{"term":"THERMAL BURN","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"THORACIC VERTEBRAL FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"TIBIA FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"TOXICITY TO VARIOUS AGENTS","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"TRANSFUSION-RELATED ACUTE LUNG INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"TRAUMATIC ARTHRITIS","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"TRAUMATIC HAEMATOMA","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"TRAUMATIC HAEMORRHAGE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"TRAUMATIC INTRACRANIAL HAEMORRHAGE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"TRAUMATIC LIVER INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ULNA FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"UPPER LIMB FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":13186}]},{"term":"VACCINATION COMPLICATION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"VASCULAR INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"VASCULAR PSEUDOANEURYSM","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":13186}]},{"term":"WOUND","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"WOUND DEHISCENCE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"WOUND EVISCERATION","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"WOUND HAEMORRHAGE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"WOUND NECROSIS","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"WRIST FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"ALANINE AMINOTRANSFERASE INCREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ASPARTATE AMINOTRANSFERASE INCREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"BLOOD CREATINE PHOSPHOKINASE INCREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"BLOOD GLUCOSE DECREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BLOOD TRIGLYCERIDES INCREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"CARDIAC STRESS TEST ABNORMAL","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CLOSTRIDIUM TEST POSITIVE","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"EJECTION FRACTION","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"EJECTION FRACTION ABNORMAL","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"EJECTION FRACTION DECREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"EXERCISE ELECTROCARDIOGRAM ABNORMAL","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"EXERCISE TEST ABNORMAL","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HAEMATOCRIT DECREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HAEMOGLOBIN DECREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"HEPATIC ENZYME ABNORMAL","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HEPATIC ENZYME INCREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HIV TEST POSITIVE","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"INTERNATIONAL NORMALISED RATIO INCREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"OCCULT BLOOD","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"OCCULT BLOOD POSITIVE","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PLATELET COUNT ABNORMAL","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PLATELET COUNT DECREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"PRECANCEROUS CELLS PRESENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PROTEIN URINE PRESENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PULMONARY FUNCTION TEST DECREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"RED BLOOD CELL COUNT DECREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"RED BLOOD CELLS URINE POSITIVE","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"TRANSAMINASES INCREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"WEIGHT DECREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"WHITE BLOOD CELL COUNT DECREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"WHITE BLOOD CELL COUNT INCREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"DEHYDRATION","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":33,"numAtRisk":13166},{"groupId":"EG001","numEvents":28,"numAffected":28,"numAtRisk":13186}]},{"term":"DIABETES MELLITUS","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":13166},{"groupId":"EG001","numEvents":23,"numAffected":22,"numAtRisk":13186}]},{"term":"DIABETES MELLITUS INADEQUATE CONTROL","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":13166},{"groupId":"EG001","numEvents":17,"numAffected":16,"numAtRisk":13186}]},{"term":"DIABETIC COMPLICATION","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"DIABETIC FOOT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":13186}]},{"term":"DIABETIC KETOACIDOSIS","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":13186}]},{"term":"ELECTROLYTE IMBALANCE","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"FAILURE TO THRIVE","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"FLUID OVERLOAD","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":13186}]},{"term":"GOUT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":13186}]},{"term":"HAEMOSIDEROSIS","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HYPERGLYCAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":19,"numAtRisk":13166},{"groupId":"EG001","numEvents":19,"numAffected":18,"numAtRisk":13186}]},{"term":"HYPERKALAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"HYPERVOLAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HYPOGLYCAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":17,"numAtRisk":13166},{"groupId":"EG001","numEvents":26,"numAffected":23,"numAtRisk":13186}]},{"term":"HYPOKALAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"HYPONATRAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"HYPOPHAGIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HYPOVOLAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"IRON METABOLISM DISORDER","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MALNUTRITION","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"METABOLIC ACIDOSIS","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"OBESITY","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"TYPE 1 DIABETES MELLITUS","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"TYPE 2 DIABETES MELLITUS","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"VITAMIN B12 DEFICIENCY","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ARTHRALGIA","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"ARTHRITIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":20,"numAtRisk":13166},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":13186}]},{"term":"ARTHROFIBROSIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ARTHROPATHY","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"BACK PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":16,"numAtRisk":13166},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":13186}]},{"term":"BONE CYST","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BONE FISTULA","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BONE PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"BURSITIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"CERVICAL SPINAL STENOSIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"CHONDROMALACIA","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"COMPARTMENT SYNDROME","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"COSTOCHONDRITIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"DUPUYTREN'S CONTRACTURE","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"EXOSTOSIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"FIBROMYALGIA","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"FLANK PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"FOOT DEFORMITY","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"FRACTURE NONUNION","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"GOUTY ARTHRITIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"GROIN PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HAEMARTHROSIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"INTERVERTEBRAL DISC DEGENERATION","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":13166},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":13186}]},{"term":"INTERVERTEBRAL DISC DISORDER","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"INTERVERTEBRAL DISC PROTRUSION","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":31,"numAtRisk":13166},{"groupId":"EG001","numEvents":19,"numAffected":19,"numAtRisk":13186}]},{"term":"LIGAMENT LAXITY","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LUMBAR SPINAL STENOSIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"MENISCAL DEGENERATION","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MONARTHRITIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MUSCLE ATROPHY","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MUSCLE HAEMORRHAGE","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"MUSCLE SPASMS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MUSCULAR WEAKNESS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"MUSCULOSKELETAL CHEST PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":27,"numAtRisk":13166},{"groupId":"EG001","numEvents":44,"numAffected":41,"numAtRisk":13186}]},{"term":"MUSCULOSKELETAL DISCOMFORT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MUSCULOSKELETAL PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":17,"numAtRisk":13166},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":13186}]},{"term":"MUSCULOSKELETAL STIFFNESS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MYALGIA","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"MYOFASCIAL PAIN SYNDROME","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MYOSITIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"NEUROPATHIC ARTHROPATHY","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"OSTEITIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"OSTEOARTHRITIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":89,"numAffected":84,"numAtRisk":13166},{"groupId":"EG001","numEvents":76,"numAffected":71,"numAtRisk":13186}]},{"term":"OSTEOCHONDROSIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"OSTEOLYSIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"OSTEONECROSIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"OSTEOPOROSIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PAIN IN EXTREMITY","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":13186}]},{"term":"PAIN IN JAW","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PERIARTHRITIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"POLYARTHRITIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"POLYMYALGIA RHEUMATICA","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PSEUDARTHROSIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"RHABDOMYOLYSIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"RHEUMATOID ARTHRITIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"ROTATOR CUFF SYNDROME","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":13166},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":13186}]},{"term":"SCOLIOSIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SPINAL COLUMN STENOSIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":21,"numAtRisk":13166},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":13186}]},{"term":"SPINAL DISORDER","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SPINAL OSTEOARTHRITIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":13166},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":13186}]},{"term":"SPONDYLITIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"SPONDYLOLISTHESIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SYMPATHETIC POSTERIOR CERVICAL SYNDROME","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SYNOVIAL CYST","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"SYSTEMIC LUPUS ERYTHEMATOSUS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"TENDON DISORDER","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"TENDON NECROSIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"TENDONITIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"TENOSYNOVITIS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"TRIGGER FINGER","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"VERTEBRAL WEDGING","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ACUTE LEUKAEMIA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ACUTE LYMPHOCYTIC LEUKAEMIA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ACUTE MYELOID LEUKAEMIA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"ADENOCARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"ADENOMA BENIGN","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ADRENAL ADENOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ADRENAL NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ANAL CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"ANAL NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ANOGENITAL WARTS","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ASTROCYTOMA MALIGNANT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ATYPICAL FIBROXANTHOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"B-CELL LYMPHOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BASAL CELL CARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":14,"numAtRisk":13166},{"groupId":"EG001","numEvents":15,"numAffected":14,"numAtRisk":13186}]},{"term":"BENIGN CARDIAC NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BENIGN LUNG NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"BENIGN NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BENIGN NEOPLASM OF BLADDER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BENIGN NEOPLASM OF SKIN","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BENIGN NEOPLASM OF TESTIS","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BENIGN NEOPLASM OF THYROID GLAND","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BENIGN RENAL NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BENIGN SALIVARY GLAND NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BILE DUCT CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":13186}]},{"term":"BILIARY CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"BILIARY NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BLADDER CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":21,"numAtRisk":13166},{"groupId":"EG001","numEvents":25,"numAffected":25,"numAtRisk":13186}]},{"term":"BLADDER CANCER RECURRENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":13186}]},{"term":"BLADDER NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"BLADDER PAPILLOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BLADDER TRANSITIONAL CELL CARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"BONE NEOPLASM MALIGNANT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BRAIN NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"BREAST CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":19,"numAtRisk":13166},{"groupId":"EG001","numEvents":17,"numAffected":17,"numAtRisk":13186}]},{"term":"BREAST CANCER IN SITU","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BREAST CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"BREAST CANCER RECURRENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BREAST NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BRONCHIAL CARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"BRONCHIOLOALVEOLAR CARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CARCINOID TUMOUR OF THE DUODENUM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CARCINOMA IN SITU","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"CERVIX CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"CERVIX CARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CHLOROMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"CHOLESTEATOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"CHONDROMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CHONDROSARCOMA METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CHOROID MELANOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CHRONIC LYMPHOCYTIC LEUKAEMIA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"CHRONIC MYELOID LEUKAEMIA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"COLON ADENOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"COLON CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":25,"numAtRisk":13166},{"groupId":"EG001","numEvents":27,"numAffected":27,"numAtRisk":13186}]},{"term":"COLON CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":13186}]},{"term":"COLON CANCER STAGE 0","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"COLON NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"COLORECTAL CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CONNECTIVE TISSUE NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ENDOMETRIAL CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ESSENTIAL THROMBOCYTHAEMIA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"FIBROUS HISTIOCYTOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GASTRIC ADENOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"GASTRIC CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"GASTRIC CANCER STAGE III","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"GASTRIC NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GASTROINTESTINAL CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GASTROINTESTINAL CARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"GASTROINTESTINAL TRACT ADENOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"GLIOBLASTOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"GLIOBLASTOMA MULTIFORME","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HAEMANGIOMA OF SPLEEN","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HEPATIC ANGIOSARCOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HEPATIC CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HEPATIC NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HEPATIC NEOPLASM MALIGNANT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"HEPATIC NEOPLASM MALIGNANT RECURRENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HODGKIN'S DISEASE","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HYPOPHARYNGEAL CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HYPOPHARYNGEAL CANCER STAGE III","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"INFECTED NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"INTESTINAL ADENOCARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"INTRADUCTAL PAPILLOMA OF BREAST","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"KERATOACANTHOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LARGE CELL CARCINOMA OF THE RESPIRATORY TRACT STAGE UNSPECIFIED","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LARGE CELL LUNG CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LARGE GRANULAR LYMPHOCYTOSIS","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LARYNGEAL CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"LARYNGEAL CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LARYNGEAL CANCER STAGE 0","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LARYNGEAL NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LEIOMYOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LEIOMYOSARCOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LEIOMYOSARCOMA METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LEUKAEMIA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LIP AND/OR ORAL CAVITY CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LIP NEOPLASM MALIGNANT STAGE UNSPECIFIED","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LIPOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"LIPOSARCOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LUNG ADENOCARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":13186}]},{"term":"LUNG ADENOCARCINOMA METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"LUNG ADENOCARCINOMA RECURRENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LUNG CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":27,"numAtRisk":13166},{"groupId":"EG001","numEvents":18,"numAffected":18,"numAtRisk":13186}]},{"term":"LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE IV","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"LUNG NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"LUNG NEOPLASM MALIGNANT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":29,"numAtRisk":13166},{"groupId":"EG001","numEvents":29,"numAffected":29,"numAtRisk":13186}]},{"term":"LUNG SQUAMOUS CELL CARCINOMA METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LUNG SQUAMOUS CELL CARCINOMA STAGE I","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LUNG SQUAMOUS CELL CARCINOMA STAGE IV","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"LYMPHANGIOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LYMPHOCYTIC LEUKAEMIA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LYMPHOCYTIC LYMPHOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LYMPHOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"MALIGNANT FIBROUS HISTIOCYTOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MALIGNANT GLIOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MALIGNANT MELANOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"MALIGNANT NEOPLASM OF EYE","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MALIGNANT PLEURAL EFFUSION","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MANTLE CELL LYMPHOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MELANOMA RECURRENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MENINGIOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MENINGIOMA BENIGN","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MESOTHELIOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MESOTHELIOMA MALIGNANT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"METASTASES TO BONE","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"METASTASES TO CENTRAL NERVOUS SYSTEM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"METASTASES TO LIVER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"METASTASES TO LUNG","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"METASTASES TO PERITONEUM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"METASTASIS","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"METASTATIC BRONCHIAL CARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"METASTATIC CARCINOMA OF THE BLADDER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"METASTATIC GASTRIC CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"METASTATIC LYMPHOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"METASTATIC MALIGNANT MELANOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"METASTATIC NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"METASTATIC SALIVARY GLAND CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"METASTATIC SQUAMOUS CELL CARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"MONOCLONAL GAMMOPATHY","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MULTIPLE MYELOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"MYELODYSPLASTIC SYNDROME","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MYELOID LEUKAEMIA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"NASOPHARYNGEAL CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"NASOPHARYNGEAL CANCER RECURRENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"NEOPLASM MALIGNANT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"NEOPLASM PROSTATE","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"NEUROENDOCRINE CARCINOMA METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"NEUROMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"NON-HODGKIN'S LYMPHOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"NON-HODGKIN'S LYMPHOMA METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"NON-HODGKIN'S LYMPHOMA RECURRENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"NON-HODGKIN'S LYMPHOMA STAGE II","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"NON-SMALL CELL LUNG CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":13186}]},{"term":"NON-SMALL CELL LUNG CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"NON-SMALL CELL LUNG CANCER STAGE IIIB","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"NON-SMALL CELL LUNG CANCER STAGE IV","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"OESOPHAGEAL ADENOCARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"OESOPHAGEAL CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"OESOPHAGEAL CARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"OESOPHAGEAL SQUAMOUS CELL CARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ORAL CAVITY CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":13186}]},{"term":"ORAL PAPILLOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"OROPHARYNGEAL CANCER STAGE UNSPECIFIED","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"OSTEOCHONDROMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"OVARIAN ADENOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"OVARIAN CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"OVARIAN CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"OVARIAN EPITHELIAL CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"OVARIAN NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PANCREATIC CARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"PANCREATIC CARCINOMA METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":13166},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":13186}]},{"term":"PAPILLOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PARAPROTEINAEMIA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PARATHYROID TUMOUR BENIGN","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PENIS CARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PENIS CARCINOMA STAGE II","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PHARYNGEAL CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PITUITARY TUMOUR","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"PITUITARY TUMOUR BENIGN","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"PLEURAL MESOTHELIOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"POLYCYTHAEMIA VERA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"PROSTATE CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":54,"numAffected":54,"numAtRisk":13166},{"groupId":"EG001","numEvents":39,"numAffected":38,"numAtRisk":13186}]},{"term":"PROSTATE CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":13166},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":13186}]},{"term":"PROSTATE CANCER RECURRENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PROSTATE CANCER STAGE I","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PROSTATE CANCER STAGE II","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PROSTATE CANCER STAGE IV","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PROSTATIC ADENOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"RECTAL ADENOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"RECTAL CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"RECTOSIGMOID CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"RENAL CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"RENAL CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"RENAL CANCER STAGE III","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"RENAL CELL CARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"RENAL CELL CARCINOMA RECURRENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"RENAL NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"RENAL ONCOCYTOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"RHABDOMYOSARCOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SALIVARY GLAND CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SALIVARY GLAND NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SEBORRHOEIC KERATOSIS","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SKIN CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"SKIN NEOPLASM BLEEDING","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SMALL CELL CARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SMALL CELL LUNG CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SMALL CELL LUNG CANCER STAGE UNSPECIFIED","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"SMALL INTESTINE CARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SMALL INTESTINE CARCINOMA METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SQUAMOUS CELL CARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":13186}]},{"term":"SQUAMOUS CELL CARCINOMA OF SKIN","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"SQUAMOUS CELL CARCINOMA OF THE CERVIX","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"T-CELL LYMPHOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"THYMOMA MALIGNANT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"THYROID ADENOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"THYROID CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"THYROID CANCER METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"TONSIL CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"TRANSITIONAL CELL CARCINOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":13186}]},{"term":"TRANSITIONAL CELL CARCINOMA METASTATIC","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"TUMOUR HAEMORRHAGE","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"URETERAL NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"URETERIC CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"UTERINE CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"UTERINE LEIOMYOMA","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"UTERINE NEOPLASM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"VULVAL CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ALTERED STATE OF CONSCIOUSNESS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"AMYOTROPHIC LATERAL SCLEROSIS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"ATAXIA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"AUTONOMIC NERVOUS SYSTEM IMBALANCE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BASAL GANGLIA HAEMORRHAGE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BRAIN OEDEMA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BRAIN STEM HAEMORRHAGE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"CAROTID ARTERY ANEURYSM","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CAROTID ARTERY STENOSIS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"CARPAL TUNNEL SYNDROME","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CAUDA EQUINA SYNDROME","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CEREBRAL AMYLOID ANGIOPATHY","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CEREBRAL CYST","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CEREBRAL HAEMORRHAGE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"CEREBRAL INFARCTION","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CEREBROVASCULAR ACCIDENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"CEREBROVASCULAR INSUFFICIENCY","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"CERVICAL MYELOPATHY","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"CERVICOBRACHIAL SYNDROME","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"CNS VENTRICULITIS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"COGNITIVE DISORDER","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"COMA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"COMPLEX PARTIAL SEIZURES","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"COMPLEX REGIONAL PAIN SYNDROME","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"COMPLICATED MIGRAINE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"CONVULSION","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":24,"numAtRisk":13166},{"groupId":"EG001","numEvents":19,"numAffected":18,"numAtRisk":13186}]},{"term":"CRANIAL NERVE PARALYSIS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"CUBITAL TUNNEL SYNDROME","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"DEMENTIA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"DEMENTIA ALZHEIMER'S TYPE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"DEMYELINATING POLYNEUROPATHY","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"DIABETIC COMA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"DIABETIC NEUROPATHY","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"DIZZINESS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":13186}]},{"term":"DIZZINESS EXERTIONAL","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"DIZZINESS POSTURAL","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"DYSAESTHESIA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"DYSARTHRIA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ENCEPHALITIS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ENCEPHALOMYELITIS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ENCEPHALOPATHY","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"EPILEPSY","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":15,"numAtRisk":13166},{"groupId":"EG001","numEvents":22,"numAffected":20,"numAtRisk":13186}]},{"term":"FACIAL PARESIS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GRAND MAL CONVULSION","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"GUILLAIN-BARRE SYNDROME","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"HAEMORRHAGE INTRACRANIAL","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":43,"numAffected":42,"numAtRisk":13166},{"groupId":"EG001","numEvents":75,"numAffected":75,"numAtRisk":13186}]},{"term":"HAEMORRHAGIC CEREBRAL INFARCTION","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HAEMORRHAGIC STROKE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"HAEMORRHAGIC TRANSFORMATION STROKE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"HEADACHE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":13166},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":13186}]},{"term":"HEMIANOPIA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HEMIPARESIS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"HYDROCEPHALUS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HYPERTENSIVE ENCEPHALOPATHY","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HYPOAESTHESIA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HYPOGLYCAEMIC COMA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"HYPOXIC-ISCHAEMIC ENCEPHALOPATHY","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"IIIRD NERVE PARALYSIS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"INTERCOSTAL NEURALGIA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"INTRACRANIAL ANEURYSM","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"INTRACRANIAL HAEMATOMA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"INTRACRANIAL HYPOTENSION","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"INTRAVENTRICULAR HAEMORRHAGE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LETHARGY","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LEUKOENCEPHALOPATHY","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LEWIS-SUMNER SYNDROME","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LOSS OF CONSCIOUSNESS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"LUMBAR RADICULOPATHY","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"MENTAL IMPAIRMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"METABOLIC ENCEPHALOPATHY","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MIGRAINE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":13186}]},{"term":"MONOPLEGIA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MYELOPATHY","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MYOCLONUS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"NERVE COMPRESSION","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"NERVE ROOT COMPRESSION","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"NERVOUS SYSTEM DISORDER","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"NEURALGIA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"NEURITIS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"NEUROLOGICAL SYMPTOM","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"NEUROPATHY PERIPHERAL","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"NORMAL PRESSURE HYDROCEPHALUS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"PARAESTHESIA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":13186}]},{"term":"PARAPARESIS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PARAPLEGIA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PARKINSON'S DISEASE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":13186}]},{"term":"PARKINSONISM","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PARTIAL SEIZURES","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PARTIAL SEIZURES WITH SECONDARY GENERALISATION","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PERIPHERAL NERVE LESION","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"POLYNEUROPATHY","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":13186}]},{"term":"PRESYNCOPE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":20,"numAtRisk":13166},{"groupId":"EG001","numEvents":22,"numAffected":21,"numAtRisk":13186}]},{"term":"PUTAMEN HAEMORRHAGE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"QUADRIPARESIS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"RADICULITIS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"RADICULOPATHY","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SCIATICA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"SEDATION","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SOMNOLENCE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SPINAL CLAUDICATION","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"SPINAL CORD COMPRESSION","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"STATUS EPILEPTICUS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"SUBARACHNOID HAEMORRHAGE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":13186}]},{"term":"SYNCOPE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":65,"numAffected":60,"numAtRisk":13166},{"groupId":"EG001","numEvents":87,"numAffected":81,"numAtRisk":13186}]},{"term":"SYRINGOMYELIA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"TENSION HEADACHE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"THORACIC OUTLET SYNDROME","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"TRANSIENT GLOBAL AMNESIA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"TREMOR","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"TRIGEMINAL NEURALGIA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"ULNAR NEURITIS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"UPPER MOTOR NEURONE LESION","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":13186}]},{"term":"VASCULAR DEMENTIA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":13186}]},{"term":"VASCULAR PARKINSONISM","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"VERTEBRAL ARTERY STENOSIS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"VIITH NERVE PARALYSIS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"VITH NERVE PARALYSIS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"VOCAL CORD PARALYSIS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"WERNICKE'S ENCEPHALOPATHY","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ABORTION MISSED","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ADJUSTMENT DISORDER","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ALCOHOL ABUSE","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ALCOHOLISM","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"ANXIETY","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":13166},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":13186}]},{"term":"ANXIETY DISORDER","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BIPOLAR DISORDER","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"BIPOLAR I DISORDER","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"COMPLETED SUICIDE","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"CONFUSIONAL STATE","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"CONVERSION DISORDER","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"DELIRIUM","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"DEPRESSED MOOD","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"DEPRESSION","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":19,"numAtRisk":13166},{"groupId":"EG001","numEvents":19,"numAffected":18,"numAtRisk":13186}]},{"term":"HALLUCINATION","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"MAJOR DEPRESSION","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":13186}]},{"term":"MANIA","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MENTAL DISORDER","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MENTAL STATUS CHANGES","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"PANIC ATTACK","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"POLYDIPSIA PSYCHOGENIC","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"POST STROKE DEPRESSION","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"PSYCHOTIC DISORDER","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"RESTLESSNESS","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SCHIZOPHRENIA","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SOMATOFORM DISORDER","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"STRESS","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SUBSTANCE ABUSE","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SUICIDAL IDEATION","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":13186}]},{"term":"SUICIDE ATTEMPT","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"TRANSIENT PSYCHOSIS","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ACUTE PRERENAL FAILURE","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"AZOTAEMIA","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BLADDER DISORDER","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BLADDER NECK OBSTRUCTION","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"BLADDER NECK SCLEROSIS","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BLADDER OUTLET OBSTRUCTION","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BLADDER PERFORATION","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BLADDER PROLAPSE","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BLADDER SPASM","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BLADDER STENOSIS","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"CALCULUS BLADDER","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"CALCULUS URETERIC","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"CALCULUS URETHRAL","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"CALCULUS URINARY","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"CYSTITIS HAEMORRHAGIC","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CYSTITIS NONINFECTIVE","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"DIABETIC NEPHROPATHY","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"DYSURIA","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"GLOMERULONEPHRITIS","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GLOMERULONEPHRITIS MEMBRANOUS","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HAEMATURIA","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":38,"numAtRisk":13166},{"groupId":"EG001","numEvents":72,"numAffected":66,"numAtRisk":13186}]},{"term":"HAEMORRHAGE URINARY TRACT","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":13186}]},{"term":"HYDRONEPHROSIS","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"HYDROURETER","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"KIDNEY FIBROSIS","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"MICTURITION URGENCY","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"NEPHROLITHIASIS","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":28,"numAtRisk":13166},{"groupId":"EG001","numEvents":22,"numAffected":22,"numAtRisk":13186}]},{"term":"NEPHROPATHY","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"NEPHROTIC SYNDROME","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"OBSTRUCTIVE UROPATHY","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PELVI-URETERIC OBSTRUCTION","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"POLYURIA","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"RENAL ARTERY OCCLUSION","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"RENAL ARTERY STENOSIS","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"RENAL COLIC","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"RENAL CYST","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"RENAL FAILURE","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":40,"numAtRisk":13166},{"groupId":"EG001","numEvents":34,"numAffected":33,"numAtRisk":13186}]},{"term":"RENAL FAILURE ACUTE","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":61,"numAffected":54,"numAtRisk":13166},{"groupId":"EG001","numEvents":44,"numAffected":43,"numAtRisk":13186}]},{"term":"RENAL FAILURE CHRONIC","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":18,"numAtRisk":13166},{"groupId":"EG001","numEvents":13,"numAffected":9,"numAtRisk":13186}]},{"term":"RENAL IMPAIRMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"RENAL INFARCT","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"RENAL MASS","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"RENAL TUBULAR NECROSIS","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"STAG HORN CALCULUS","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"STRESS URINARY INCONTINENCE","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"TUBULOINTERSTITIAL NEPHRITIS","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"URETERIC RUPTURE","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"URETERIC STENOSIS","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"URETHRAL OBSTRUCTION","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"URETHRAL STENOSIS","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":13186}]},{"term":"URINARY BLADDER POLYP","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"URINARY INCONTINENCE","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"URINARY RETENTION","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"URINARY TRACT DISORDER","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"VESICOURETERIC REFLUX","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BALANITIS","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BENIGN PROSTATIC HYPERPLASIA","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":27,"numAtRisk":13166},{"groupId":"EG001","numEvents":36,"numAffected":35,"numAtRisk":13186}]},{"term":"BREAST ENLARGEMENT","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"CYSTOCELE","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ENDOMETRIAL HYPERPLASIA","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"EPIDIDYMITIS","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ERECTILE DYSFUNCTION","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"FIBROCYSTIC BREAST DISEASE","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"GENITAL HAEMORRHAGE","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"GENITAL TRACT INFLAMMATION","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MENOMETRORRHAGIA","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"MENORRHAGIA","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":13186}]},{"term":"MENSTRUAL DISORDER","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"METRORRHAGIA","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ORCHITIS NONINFECTIVE","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"OVARIAN CYST","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"PELVIC HAEMATOMA","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PELVIC PROLAPSE","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"POSTMENOPAUSAL HAEMORRHAGE","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PROSTATIC HAEMORRHAGE","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PROSTATISM","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PROSTATITIS","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"PROSTATOMEGALY","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"RECTOCELE","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"SPERMATOCELE","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"TESTICULAR OEDEMA","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"UTERINE CYST","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"UTERINE HAEMORRHAGE","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"UTERINE PROLAPSE","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"UTEROVAGINAL PROLAPSE","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"VAGINAL HAEMORRHAGE","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"VAGINAL LACERATION","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"VAGINAL PROLAPSE","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"VAGINAL ULCERATION","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ACUTE PULMONARY OEDEMA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":13186}]},{"term":"ACUTE RESPIRATORY DISTRESS SYNDROME","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"ACUTE RESPIRATORY FAILURE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":18,"numAtRisk":13166},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":13186}]},{"term":"ADENOIDAL DISORDER","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"APNOEA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ASPHYXIA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ASTHMA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":8,"numAtRisk":13166},{"groupId":"EG001","numEvents":15,"numAffected":12,"numAtRisk":13186}]},{"term":"ATELECTASIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BRAIN HYPOXIA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"BRONCHIAL HYPERREACTIVITY","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"BRONCHOSPASM","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":100,"numAffected":75,"numAtRisk":13166},{"groupId":"EG001","numEvents":112,"numAffected":79,"numAtRisk":13186}]},{"term":"COUGH","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"DIAPHRAGMATIC PARALYSIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"DYSPNOEA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":18,"numAtRisk":13166},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":13186}]},{"term":"DYSPNOEA EXERTIONAL","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"DYSPNOEA PAROXYSMAL NOCTURNAL","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"EMPHYSEMA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"EOSINOPHILIC PNEUMONIA ACUTE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"EPISTAXIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":16,"numAtRisk":13166},{"groupId":"EG001","numEvents":30,"numAffected":29,"numAtRisk":13186}]},{"term":"HAEMOPTYSIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":13166},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":13186}]},{"term":"HAEMOTHORAX","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"HYDROTHORAX","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"HYPERVENTILATION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HYPOVENTILATION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HYPOXIA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"IDIOPATHIC PULMONARY FIBROSIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"INTERSTITIAL LUNG DISEASE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"LARYNGEAL MASS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LARYNGEAL STENOSIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LUNG CONSOLIDATION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LUNG DISORDER","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"NASAL POLYPS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"NASAL SEPTUM DEVIATION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"NASAL SEPTUM DISORDER","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"NASAL TURBINATE HYPERTROPHY","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"OBSTRUCTIVE AIRWAYS DISORDER","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PHARYNGEAL HAEMORRHAGE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PLEURAL EFFUSION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":13166},{"groupId":"EG001","numEvents":14,"numAffected":13,"numAtRisk":13186}]},{"term":"PLEURISY","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PLEURITIC PAIN","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PNEUMONIA ASPIRATION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":12,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"PNEUMONITIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"PNEUMOTHORAX","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":13166},{"groupId":"EG001","numEvents":13,"numAffected":9,"numAtRisk":13186}]},{"term":"PULMONARY CALCIFICATION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PULMONARY CONGESTION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"PULMONARY EMBOLISM","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":45,"numAffected":45,"numAtRisk":13166},{"groupId":"EG001","numEvents":24,"numAffected":23,"numAtRisk":13186}]},{"term":"PULMONARY FIBROSIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"PULMONARY HAEMORRHAGE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PULMONARY HYPERTENSION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PULMONARY INFARCTION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PULMONARY MASS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PULMONARY NECROSIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PULMONARY OEDEMA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":13166},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":13186}]},{"term":"RESPIRATORY ACIDOSIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"RESPIRATORY ARREST","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"RESPIRATORY DISTRESS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":13186}]},{"term":"RESPIRATORY FAILURE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":13166},{"groupId":"EG001","numEvents":22,"numAffected":21,"numAtRisk":13186}]},{"term":"RHINITIS ALLERGIC","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SINUS POLYP","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SLEEP APNOEA SYNDROME","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":13186}]},{"term":"TONSILLAR HAEMORRHAGE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"VOCAL CORD ATROPHY","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"VOCAL CORD POLYP","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"WHEEZING","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ANGIODERMATITIS","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ANGIOEDEMA","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"DECUBITUS ULCER","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"DERMATITIS","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"DERMATITIS ALLERGIC","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"DERMATITIS EXFOLIATIVE","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"DERMATOMYOSITIS","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"DIABETIC DERMOPATHY","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"DIABETIC ULCER","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"DRY GANGRENE","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ECCHYMOSIS","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"ECZEMA","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"HYPERHIDROSIS","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LEUKOCYTOCLASTIC VASCULITIS","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PEMPHIGOID","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PEMPHIGUS","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PETECHIAE","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PSORIASIS","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"PURPURA","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"RASH","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SCAR","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SEGMENTED HYALINISING VASCULITIS","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SKIN HAEMORRHAGE","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"SKIN NECROSIS","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SKIN ULCER","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"STASIS DERMATITIS","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"URTICARIA","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SOCIAL PROBLEM","organSystem":"Social circumstances","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ABDOMINAL OPERATION","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"FINGER AMPUTATION","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"GASTRIC BANDING","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HIP ARTHROPLASTY","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"INGUINAL HERNIA REPAIR","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"POLYPECTOMY","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SPINAL DECOMPRESSION","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SURGERY","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ACCELERATED HYPERTENSION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ANEURYSM","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ANEURYSM RUPTURED","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ANGIODYSPLASIA","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"AORTIC ANEURYSM","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":18,"numAtRisk":13166},{"groupId":"EG001","numEvents":18,"numAffected":18,"numAtRisk":13186}]},{"term":"AORTIC ANEURYSM RUPTURE","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":13186}]},{"term":"AORTIC DILATATION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"AORTIC DISSECTION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":13186}]},{"term":"AORTIC STENOSIS","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13166},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":13186}]},{"term":"ARTERIAL DISORDER","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ARTERIAL HAEMORRHAGE","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ARTERIAL RUPTURE","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":13186}]},{"term":"ARTERIOSCLEROSIS","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"ARTERIOVENOUS FISTULA","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"BLEEDING VARICOSE VEIN","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":13186}]},{"term":"CIRCULATORY COLLAPSE","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"DEEP VEIN THROMBOSIS","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":22,"numAtRisk":13166},{"groupId":"EG001","numEvents":20,"numAffected":19,"numAtRisk":13186}]},{"term":"ESSENTIAL HYPERTENSION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"EXTREMITY NECROSIS","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"FEMORAL ARTERY ANEURYSM","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HAEMATOMA","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":16,"numAtRisk":13166},{"groupId":"EG001","numEvents":26,"numAffected":25,"numAtRisk":13186}]},{"term":"HAEMODYNAMIC INSTABILITY","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HAEMORRHAGE","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":23,"numAtRisk":13166},{"groupId":"EG001","numEvents":40,"numAffected":36,"numAtRisk":13186}]},{"term":"HYPERTENSION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":26,"numAtRisk":13166},{"groupId":"EG001","numEvents":32,"numAffected":27,"numAtRisk":13186}]},{"term":"HYPERTENSIVE CRISIS","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":31,"numAtRisk":13166},{"groupId":"EG001","numEvents":25,"numAffected":20,"numAtRisk":13186}]},{"term":"HYPERTENSIVE EMERGENCY","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13166},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":13186}]},{"term":"HYPOPERFUSION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"HYPOTENSION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":29,"numAtRisk":13166},{"groupId":"EG001","numEvents":31,"numAffected":31,"numAtRisk":13186}]},{"term":"HYPOVOLAEMIC SHOCK","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"INTRA-ABDOMINAL HAEMORRHAGE","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LABILE BLOOD PRESSURE","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LYMPHATIC FISTULA","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"LYMPHOCELE","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"LYMPHOEDEMA","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"MALIGNANT HYPERTENSION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ORTHOSTATIC HYPERTENSION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"ORTHOSTATIC HYPOTENSION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":20,"numAtRisk":13166},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":13186}]},{"term":"PERIPHERAL ARTERY ANEURYSM","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"PERIPHERAL EMBOLISM","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"PHLEBITIS","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"POOR PERIPHERAL CIRCULATION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"RAYNAUD'S PHENOMENON","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"SHOCK","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"SUBCLAVIAN VEIN THROMBOSIS","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":13186}]},{"term":"TEMPORAL ARTERITIS","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"VARICOSE VEIN","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":13186}]},{"term":"VENOUS INSUFFICIENCY","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]},{"term":"VENOUS THROMBOSIS","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13166},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":13186}]},{"term":"WEGENER'S GRANULOMATOSIS","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13166},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":13186}]}],"otherEvents":[{"term":"CHEST PAIN","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":785,"numAffected":687,"numAtRisk":13166},{"groupId":"EG001","numEvents":789,"numAffected":672,"numAtRisk":13186}]},{"term":"DIZZINESS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":781,"numAffected":704,"numAtRisk":13166},{"groupId":"EG001","numEvents":746,"numAffected":662,"numAtRisk":13186}]},{"term":"EPISTAXIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":513,"numAffected":401,"numAtRisk":13166},{"groupId":"EG001","numEvents":1044,"numAffected":807,"numAtRisk":13186}]},{"term":"HYPERTENSION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":789,"numAffected":736,"numAtRisk":13166},{"groupId":"EG001","numEvents":761,"numAffected":712,"numAtRisk":13186}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Prior to the completion of the study, based on a communication from the Data and Safety Monitoring Board, all participants who had experienced a stroke either before or during the study had study drug discontinued."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The investigators agreed not to publish or publicly present any interim results of the study without the prior written consent of the sponsor. The investigator further agreed to provide to the sponsor review copies of abstracts or manuscripts for publication 45 days prior to submission."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme Corp.","email":"ClinicalTrialsDisclosure@merck.com","phone":"1-800-672-6372"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","removedCountries":["Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Colombia","Czech Republic","Denmark","Finland","France","Germany","Hong Kong","Hungary","Israel","Italy","Japan","Malaysia","Netherlands","New Zealand","Norway","Poland","Portugal","Puerto Rico","Singapore","South Africa","Spain","Sweden","Switzerland","United Kingdom","United States"]},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000009203","term":"Myocardial Infarction"},{"id":"D000050197","term":"Atherosclerosis"},{"id":"D000058729","term":"Peripheral Arterial Disease"},{"id":"D000016491","term":"Peripheral Vascular Diseases"},{"id":"D000007238","term":"Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000009336","term":"Necrosis"},{"id":"D000017202","term":"Myocardial Ischemia"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000001161","term":"Arteriosclerosis"},{"id":"D000001157","term":"Arterial Occlusive Diseases"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Cerebrovascular Accident","relevance":"HIGH"},{"id":"M11997","name":"Neoplasm Metastasis","relevance":"LOW"},{"id":"M10233","name":"Ischemia","asFound":"Ischemia","relevance":"HIGH"},{"id":"M11845","name":"Myocardial Infarction","asFound":"Myocardial Infarction","relevance":"HIGH"},{"id":"M9972","name":"Infarction","asFound":"Infarction","relevance":"HIGH"},{"id":"M25878","name":"Atherosclerosis","asFound":"Atherosclerosis","relevance":"HIGH"},{"id":"M28903","name":"Peripheral Arterial Disease","asFound":"Peripheral Arterial Disease","relevance":"HIGH"},{"id":"M18584","name":"Peripheral Vascular Diseases","asFound":"Peripheral Arterial Disease","relevance":"HIGH"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"M6236","name":"Coronary Artery Disease","relevance":"LOW"},{"id":"M19196","name":"Myocardial Ischemia","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"},{"id":"M4159","name":"Arteriosclerosis","relevance":"LOW"},{"id":"M4155","name":"Arterial Occlusive Diseases","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"C000530299","term":"Vorapaxar"}],"ancestors":[{"id":"D000010975","term":"Platelet Aggregation Inhibitors"}],"browseLeaves":[{"id":"M16366","name":"Thrombin","relevance":"LOW"},{"id":"M232590","name":"Vorapaxar","asFound":"Dose-Response Relationship","relevance":"HIGH"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"}]}},"hasResults":true}